
==== Front
Hypertens Res
Hypertens Res
Hypertension Research
0916-9636
1348-4214
Springer Nature Singapore Singapore

38961282
1763
10.1038/s41440-024-01763-y
Review Article
G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic targets
Zhang Fuwei 123
Armando Ines 4
Jose Pedro A. 4
Zeng Chunyu 56
Yang Jian jianyang@hospital.cqmu.edu.cn

12
1 grid.203458.8 0000 0000 8653 0555 Research Center for Metabolic and Cardiovascular Diseases, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, PR China
2 grid.203458.8 0000 0000 8653 0555 Department of Nutrition, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, PR China
3 grid.203458.8 0000 0000 8653 0555 Department of Cardiology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, PR China
4 grid.253615.6 0000 0004 1936 9510 Division of Renal Diseases & Hypertension, Department of Medicine and Department of Physiology/Pharmacology, The George Washington University School of Medicine & Health Sciences, Washington, DC USA
5 grid.410570.7 0000 0004 1760 6682 Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University), Chongqing, PR China
6 grid.410570.7 0000 0004 1760 6682 Chongqing Key Laboratory for Hypertension Research, Chongqing Cardiovascular Clinical Research Center, Chongqing Institute of Cardiology, Chongqing, PR China
3 7 2024
3 7 2024
2024
47 9 23172336
17 11 2023
10 5 2024
6 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
G protein-coupled receptors (GPCRs) mediate cellular responses to a myriad of hormones and neurotransmitters that play vital roles in the regulation of physiological processes such as blood pressure. In organs such as the artery and kidney, hormones or neurotransmitters, such as angiotensin II (Ang II), dopamine, epinephrine, and norepinephrine exert their functions via their receptors, with the ultimate effect of keeping normal vascular reactivity, normal body sodium, and normal blood pressure. GPCR kinases (GRKs) exert their biological functions, by mediating the regulation of agonist-occupied GPCRs, non-GPCRs, or non-receptor substrates. In particular, increasing number of studies show that aberrant expression and activity of GRKs in the cardiovascular system and kidney inhibit or stimulate GPCRs (e.g., dopamine receptors, Ang II receptors, and α- and β-adrenergic receptors), resulting in hypertension. Current studies focus on the effect of selective GRK inhibitors in cardiovascular diseases, including hypertension. Moreover, genetic studies show that GRK gene variants are associated with essential hypertension, blood pressure response to antihypertensive medicines, and adverse cardiovascular outcomes of antihypertensive treatment. In this review, we present a comprehensive overview of GRK-mediated regulation of blood pressure, role of GRKs in the pathogenesis of hypertension, and highlight potential strategies for the treatment of hypertension.

Schematic representation of GPCR desensitization process. Activation of GPCRs begins with the binding of an agonist to its corresponding receptor. Then G proteins activate downstream effectors that are mediated by various signaling pathways. GPCR signaling is halted by GRK-mediated receptor phosphorylation, which causes receptor internalization through β-arrestin.

Keywords

Blood pressure
G protein-coupled receptor
G protein-coupled receptor kinase
Hypertension
issue-copyright-statement© The Japanese Society of Hypertension 2024
==== Body
pmcEssential hypertension, also known as primary hypertension, is a major contributing risk factor for cardiovascular and cerebrovascular diseases, and causes damage of target organs, such as the kidney, heart and brain [1]. Worldwide data from the Noncommunicable Disease (NCD) Risk Factor Collaboration show that the number of people 30–79 years old with hypertension has doubled from 1990 to 2019, with most of the increase occurring in low-income and middle-income regions [2]. In the United States, 46.7% (122.4 million) of adults ≥20 years of age has hypertension, and the number of deaths attributable to high blood pressure increased 90.1% from 2010 to 2020 [3]. Hypertension is a major public health problem and challenges worldwide [4].

Cells communicate with each other by receiving and sending through a myriad of extracellular proteins/molecules, such as neurotransmitters, chemoattractants, and hormones, which bind to receptors and drive the initiation of multiple intracellular signaling routes. G protein-coupled receptors (GPCRs) are the largest superfamily of cell-surface receptors and the most diverse group of proteins involved in transmembrane signal transduction [5, 6]. They share conserved seven α-helical structured transmembrane domains, extracellular ligand-binding domains, and carboxy-terminal intracellular domains. GPCRs, including adrenergic receptors, angiotensin II (Ang II) receptors, and dopamine receptors, control a variety of physiological processes involved in the regulation of blood pressure [7, 8]. Cell dysfunction, induced by aberrant GPCRs, including abnormal phosphorylation, trafficking, and expression, causes hypertension by various mechanisms [8–10].

The phosphorylation and desensitization of agonist-occupied GPCRs are primarily mediated by GPCR kinases (GRKs) [11]. As their name implies, GRKs are defined by their actions on GPCR phosphorylation, receptor internalization, and subsequent signal termination (Fig. 1). Abnormalities of GRKs are associated with cardiovascular diseases, including hypertension [12, 13]. A number of studies have shown that GRKs play a vital role in the regulation of blood pressure; aberrant expression and/or activity of GRKs cause hypertension and are associated with impaired response to antihypertensive treatment [14–17]. There are abundant epidemiological and animal studies reinforcing the role of GRKs and their underlying mechanisms in the regulation of blood pressure. Therefore, in this article, we review our evolving understanding of GRK-mediated regulation of blood pressure and highlight potential strategies for targeting GRKs in the prevention and treatment of hypertension.Fig. 1 Schematic representation of GPCR desensitization process. Activation of GPCRs begins with the binding of an agonist to its corresponding receptor. Then G proteins activate downstream effectors that are mediated by various signaling pathways. GPCR signaling is halted by GRK-mediated receptor phosphorylation, which causes receptor internalization through β-arrestin. ATP adenosine triphosphate, cAMP cyclic adenosine monophosphate, GAP GTPase activating protein, GDP Guanosine-5’-diphosphate, GEF guanine nucleotide exchange factor; GPCR G protein-coupled receptor, GRK G protein–coupled receptor kinase, GTP guanosine triphosphate, PI3K phosphatidylinositol-3 kinase, PKC protein kinase C, PLC-β phospholipase C-β; RGS regulators of G protein signaling

The Grk family

GRK-mediated receptor phosphorylation is one of the well-characterized mechanisms for GPCR desensitization. There are more than 800 distinct GPCRs in the human genome but of the vital regulators of agonist-induced phosphorylation of GPCRs, only seven GRKs (GRK1–7) have been identified [18]. Based on their sequence similarity and gene structure, the serine/threonine kinase GRK family encompasses seven protein isoforms that are classified into three subfamilies. GRK1 and GRK7 belong to the GRK1-like subfamily, also known as visual or rhodopsin-specific GRKs. GRK2 (β-adrenergic receptor kinase 1, β-ARK1) and GRK3 (β-ARK2) belong to the GRK2-like subfamily, also known as β-adrenergic receptor (β-AR) kinase subfamily. GRK4, GRK5, and GRK6 belong to the GRK4-like subfamily [17, 18].

The seven GRKs share a common general protein structure with a central catalytic domain (~270 amino acids), flanked by an amino-terminal (N-terminal) domain (~185 amino acids) and a carboxyl terminal (C- terminal) domain (~105 to 230 amino acids) [19]. The N-terminus, a well-conserved domain between GRK members, is vital for the selective recognition of the activated receptor and also contains a region termed as a regulator of G protein signaling homology (RH) domain (~120 amino acids). However, the C-terminus is divergent among GRK subfamilies and contributes to their subcellular membrane localization and agonist-dependent translocation [19, 20].

In addition to GPCRs, GRKs also regulate the phosphorylation or expression of other non-GPCR receptors, such as adiponectin receptor 1 (AdipoR1) and insulin-like growth factor-1 receptor [21, 22]. Moreover, GRKs regulate non-receptor substrates, including signaling proteins, such as insulin receptor substrate-1, nuclear proteins, such as histone deacetylase 5, and transcription factors, such as IκBα, among others [23–26]. We also reported that GRK4 increases the phosphorylation of signal transducer and activator of transcription 1 and HDAC4 [27, 28]. It should also be noted that kinase activity is not necessary for some GRK-mediated functions. For example, GRK4 regulates cilia and kidney development independent of its kinase function [29].

All GRKs are primarily localized in the cytosol and plasma membrane. However, the tissue distribution of the seven GRK subtypes is different from each other. GRK2, GRK3, GRK5, and GRK6 are ubiquitously distributed among mammalian tissues [17]. GRK1, GRK4, and GRK7 are expressed in specific tissues. GRK1 and GRK7 are expressed exclusively in the retina, whereas GRK4 is expressed in a few organs [17, 30]. These indicate that GRKs may exert different physiological functions based on their tissue distribution.

Role of Grks on blood pressure regulation

Many studies have shown that GRKs exert their biological functions by mediating the regulation of agonist-occupied GPCRs, non-GPCR receptors, and non-receptor substrates (Table 1). Several organs, including the artery, heart, and kidney, are involved in GRK-mediated blood pressure regulation (Fig. 2). The expression and/or activity of GRKs are aberrant in the hypertensive humans and animal models of hypertension. Because GRK1 and GRK7 are expressed only in the retina, only the role of the other five GRKs in the regulation of blood pressure have been studied.Table 1 GRK substrates related to the regulation of blood pressure

GRK isoform	Substrate protein	Tissue/cells	Regulation of Substrate	
GPCR substrates	
GRK2	ETAR	Rat mesenteric arterial smooth muscle cells [35]; rat aortic smooth muscle cells [37]	Inactive dominant-negative GRK2 or siRNA-Grk2 attenuates ETAR desensitization and its mediated VSMC contractile or migration signaling [35, 37]	
	P2Y2R	Rat mesenteric artery [36]; rat mesenteric arterial smooth muscle cells [36]; rat aortic smooth muscle cells [37]	GRK2 inhibition or siRNA-Grk2 attenuates P2Y2R desensitization and its mediated VSMC contractile or migration signaling [36, 37]	
	β-AR	Mouse aortic arterial smooth muscle cells [34]; brachial artery [66]; HEK293 cells [76]	VSM-targeted overexpression of Grk2 attenuates β-AR signaling and vasodilation [34]; inhibition of GRK2 activity prevents β-AR desensitization [66]; GRK2 directly interacts with β2-AR and regulates its desensitization [76]; Grk2 knockout or GRK2 inhibition increases β-AR-mediated vasodilation [39]	
	AT1R	HEK293 cells [38]; kidney [43]; heart [32]	GRK2 inhibition reduces agonist-induced AT1R phosphorylation and prevents receptor desensitization [38]; Grk2 knockdown enhances renal AT1R-mediated ROS production [43]; cardiac-specific Grk2 expression attenuates Ang II-induced increase in cardiac contractility [32]	
	D1R	Rat RPT cells [47, 49]; OK cells [48]; HEK293 cells [41, 75] and rat striatum [75]	GRK2 mediates H2O2 or insulin-caused renal D1R phosphorylation and impairs D1R-mediated inhibition of Na+-K+-ATPase activity [47, 48]; GRK2 increases D1R desensitization and phosphorylation [75]; Grk2 overexpression increases agonist-induced D1R phosphorylation [41]	
	α1D-AR	VSM	Grk2 knockout or peptide inhibition enhances α1D-AR-induced vasoconstriction [39]	
GRK3	α1-AR	Cardiac myocytes	GRK3 inhibition causes α1-AR hyper-responsiveness [73]	
	D1R	HEK293 cells; rat striatum	GRK3 increases D1R desensitization and phosphorylation [75]; Grk3 overexpression increases dopamine-induced D1R phosphorylation [41]	
	β2-AR	HEK293 cells	GRK3 directly interacts with β2-AR and regulates its desensitization [76]	
	AT1R	HEK293 cells	Grk3 overexpression increases angiotensin II-induced AT1R phosphorylation [38]	
GRK4	D1R	CHO cells [15]; HEK293T cells [85]; Human RPT cells[15, 86]; Kidney [81]; Rat renal cortex [79];	GRK4 phosphorylates the D1R, causing its constitutive desensitization and internalization [85]; GRK4 As-Odns decrease serine-phosphorylated D1R [79]; UTMD-mediated renal Grk4 siRNA delivery reduces D1R phosphorylation and blood pressure and increases D1R-mediated natriuresis and diuresis [81]; GRK4γ variants increase D1R phosphorylation and impair D1R-mediated cAMP production [15]; GRK4 inhibition blunts D1R desensitization [86]	
	D3R	Human RPT cells	GRK4γ and GRK4α increase the phosphorylation of agonist-activated D3R [91]	
	AT1R	Thoracic aortic VSM cells [77]; HEK293 cells and human RPT cells [78]; kidney [78]	hGRK4γ 142V increases AT1R expression [77, 78]	
	ETBR	Renal cortex; rat RPT cells	hGRK4γ 142V increases but GRK4 depletion decreases renal ETBR phosphorylation [82]	
	AT2R	Renal cortex; rat RPT cells	hGRK4γ 142V increases renal AT2R phosphorylation and causes its dysfunction [93]	
	CCKBR	Renal cortex; rat RPT cells	hGRK4γ 142V increases but GRK4 silencing decreases renal CCKBR phosphorylation [170]	
GRK5	AT1R	HEK293 cells	Grk5 overexpression increases the angiotensin II-induced AT1R phosphorylation [38]	
	β-AR	VSM [122]; heart [32]	VSM-Grk5 over-expression increases blood pressure to a greater extent in male than female mice; β-AR stimulation induced vasoconstriction in male mice but decreased β-AR-induced vasodilation and increased angiotensin II sensitivity in female mice [122]; Cardiac-specific Grk5 expression increases β-AR desensitization but does not affect the contractile response to angiotensin II [32]	
	D1R	HEK293 cells	Grk5 overexpression increases agonist-induced D1R phosphorylation [41]	
GRK6	D1R	Intestinal epithelial cells	GRK6 antibodies prevents the desensitization-mediated loss of D1R inhibition of Cl/HCO3- exchanger activity [130]	
Non-GPCR receptor substrates				
GRK4	adipoR1	Renal cortex; rat RPT cells	hGRK4γ 142V causes adipoR1 phosphorylation and desensitization [21]	
Non-receptor substrates				
GRK2	ENaC	Salivary duct cells	GRK2 phosphorylates S633 in the C terminus of ENaC [44]	
	Nedd4 and Nedd4-2	HEK293T cells	GRK2 phosphorylates Nedd4 and Nedd4-2 [46]	
GRK4	HDAC4	Mouse cardiomyocytes	GRK4 increases HDAC4 phosphorylation and decreases its binding to the beclin-1 promoter [28]	
	NF-κB	Embryonic rat thoracic aortic smooth muscle cells	GRK4γ 142V increases NF-κB activity with more NF-κB bound to the AT1R promoter [77]	
	STAT1	HK-2 cells and mouse kidney	GRK4 phosphorylates STAT1 [27]	
	HDAC1	Human RPT cells and mouse kidney	GRK4γ 142V phosphorylates HDAC1 and promotes its nuclear export to the cytoplasm [78]	
α-AR α-adrenergic receptor, adipoR1 adiponectin receptor 1, As-Odn antisense oligodeoxynucleotides, AT1R angiotensin II type 1 receptor, AT2R angiotensin II type 2 receptor, β-AR β-adrenergic receptor, cAMP cyclic adenosine monophosphate, CCKBR cholecystokinin receptor type B, CHO Chinese hamster ovary, D1R dopamine D1 receptor, ENaC epithelial sodium channel, ETAR endothelin receptor type A, ETBR endothelin receptor type B, GRK G protein-coupled receptor kinase, HDAC1 Histone deacetylase 1, HDAC4 Histone deacetylase 4, hGRK4γ human G protein-coupled receptor kinase 4-gamma, Nedd4 neural precursor cell expressed developmentally downregulated 4, NF-κB nuclear factor-κB, P2Y2R P2Y2 receptor, ROS reactive oxygen species, STAT1 signal transducer and activator of transcription 1, VSM vascular smooth muscle, VSMC vascular smooth muscle cell, UTMD ultrasound-targeted microbubble destruction

Fig. 2 Regulation of blood pressure by GRKs. GRKs exert their functions in organs, including kidney, artery, and heart, by regulating the expression or phosphorylation of various GPCRs to modulate blood pressure. Pink color: various substrates regulated by GRKs. α-1DAR α-1D adrenergic receptor, adipoR1 adiponectin receptor 1, Ang II angiotensin II, AT1R angiotensin II type 1 receptor, AT2R angiotensin II type 2 receptor, β-AR β-adrenergic receptor, D1R dopamine D1 receptor, D3R dopamine D3 receptor, ETBR endothelin receptor type B, GRK G protein-coupled receptor kinase, P2Y2R P2Y2 receptor

GRK2

Role of GRK2 in the regulation of blood pressure

GRK2 is ubiquitously expressed in mammalian organs and tissues, including the artery, heart, and kidney. GRK2 is not only a key regulator of vascular responsivity in resistance arteries but also regulates myocardial contractility [31, 32], and renal function (vide infra).

GRK2 regulates GPCR-mediated vascular signaling, which participates in the regulation of blood pressure. Global knockdown of GRK2 [33] or vascular smooth muscle (VSM)-targeted overexpression of GRK2 in mice increases resting blood pressure [34]. This apparent inconsistent effect on blood pressure may be related to the fact that the alteration in GRK2 expression (increased or decreased) can lead to the imbalance of vasoconstrictor and vasodilator effects, resulting in hypertension [33]. GRK2 negatively regulates GPCRs such as endothelin type A receptor [35], P2Y2 receptor [36, 37], angiotensin II type 1 receptor (AT1R) [38] and α1D-adrenergic receptor [39], which should result in vasodilation. By contrast, GRK2 also negatively regulates β2-adrenergic receptor [40] and dopamine D1 receptor (D1R)/adenylyl cyclase signaling [41], which should result in vasoconstriction. The rebound hypertension in mice that occurs after withdrawal of clonidine, an α1D, α2A-C adrenergic receptor agonist, is mitigated by an increase in nitric oxide bioavailability, an effect that is prevented by suppression of GRK2 activity [42]. However, one group reported that global GRK2 knockdown impaired kidney development, and increased blood pressure [43] while another group reported that Grk2+/− mice have normal blood pressure and attenuated response to the hypertensive effect of Ang II infusion [31]. Therefore, the overall effect of GRK2 on blood pressure is difficult to predict (vide infra).

GRK2 directly interacts with the epithelial sodium channel (ENaC) [44], which increases the reabsorption of filtered sodium across the luminal membrane of the principal cells of the aldosterone-sensitive distal nephron [45]. GRK2 positively regulates ENaC activity by phosphorylating Nedd4 and Nedd4-2, two ubiquitin-protein ligases binding with the channels, to prevent their ability to inhibit epithelial channel activity [46]. The dopaminergic system plays a vital role in the regulation of sodium excretion. The activation of GRK2 by some factors such as oxidative stress and insulin impairs the ability of renal D1R to inhibit sodium transport [47, 48] that leads to the development of hypertension [8]. We have also reported that exposure to maternal diabetes mellitus causes renal D1R dysfunction and hypertension in adult rat offspring by increasing GRK2 activity [49]. Thus, GRK2 can increase blood pressure by increasing renal sodium transport.

GRK2 also regulates receptor-mediated signaling in the heart. GRK2 phosphorylates cardiac β2-adrenergic receptor and increases Gi-biased signaling, which contributes to heart failure [50]. However, GRK2 inhibition increases β-adrenergic receptor-dependent cardiomyocyte and cardiac contractility and reverses cardiac dysfunction in heart failure models [51]. GRK2 also regulates the desensitization of other cardiac receptors, such as AdipoR1 and κ-opioid receptor [52, 53]. In addition, GRK2 participates in the regulation of other physiological or pathological functions in the heart, including fatty acid metabolism, production of NLRP3 inflammasome and oxidative stress, and modulation of insulin signaling [54–56]. How, these GRK2-mediated effects in the heart regulate blood pressure need to be studied further.

Blood pressure phenotypes in mice with modified Grk2 expression

As aforementioned, the role of GRK2 on the regulation of blood pressure has been demonstrated in mice with genetically modified Grk2 expression. Since germline deletion of Grk2 is lethal, Grk2 hemizygous mice (GRK2+/−), shRNA-GRK2 transgenic mice, or knockdown in local organs have been used to investigate its effects on the regulation of blood pressure. shRNA-induced total body knockdown of GRK2 causes spontaneous hypertension and impairs vascular reactivity [33]. This is similar to the findings of another study in which Grk2 knockdown in mice exacerbates kidney injury and causes spontaneous hypertension, accompanied with over-activation of the renal renin-angiotensin system (RAS) and AT1R signaling [43]. However, Grk2 deficiency in global adult hemizygous mice does not cause hypertension but impairs the increase in blood pressure and prevents vascular remodeling secondary to Ang II infusion [31]. By contrast, inhibition of VSM-Grk2 by overexpression of the C-terminal portion of Grk2 or VSM-specific ablation of Grk2 protein expression in mice has no effect on the increased blood pressure in the two-kidney, one-clip (2K1C) model, which may be due to a balance between the increased β-AR-mediated dilation and the enhancement of α1D-AR-stimulated vasoconstriction [39].

The reason for the inconsistent reports on the effect of Grk2 knockdown on blood pressure remains unclear. We speculate some possibilities: 1) Different methods of Grk2 knockdown may produce different effects. Global knockdown of GRK2 using a small hairpin (sh) RNA leads to hypertension [33, 43], a partial deficiency of GRK2 protects against Ang II-induced hypertension [31]; VSM-specific Grk2 knockdown has no effect on blood pressure [39]. 2) GRK2 regulates both vasoconstriction and dilation. For example, GRK2 deficiency increases phenylephrine, but not KCl-mediated constriction and isoproterenol-mediated vasodilation [33]. The dominant effect induced by GRK2 knockdown may determine the physiological or pathological phenotype. 3) Duration of Grk2 silencing. There is a balance between vasoconstriction and vasodilation in Grk2 knockdown mice. Twelve to 14 weeks of Grk2 knockdown using small hairpin RNA causes a shift toward vasoconstriction and subsequent hypertension [33]. Additionally, activated renal AT1R-mediated signaling also plays an important role in the development of hypertension after six months of Grk2 knockdown [43]. However, a longer (nine months) duration of Grk2 knockdown was reported to lead to a nitric oxide-dependent vasodilation which overcomes vasoconstriction, making Grk2+/− mice resistant to the development of hypertension [31]. 4) It is possible that the different effects on blood pressure induced by Grk2 knockdown may be also attributed to experimental conditions such as animal species and shRNA induction.

The depletion of Grk2 expression in aortic smooth muscle cells also impairs the proliferative effect of endothelin and Ang II [57], that should prevent the increase in blood pressure. Grk2 knockdown in the endothelial cells of mesenteric arterioles promotes insulin-induced vasodilation and insulin-stimulated signaling pathway in SHRs; this effect is prevented by upregulation of Grk2 [58]. Selective deletion of Grk2 in vascular endothelium of mice also blunts the vasoconstriction induced by the α1-adrenergic receptor agonist phenylephrine and other vasoconstrictors (serotonin, oxytocin, and KCl) [59].

By contrast, transgenic mice with VSM-targeted Grk2 over-expression have higher resting blood pressure than their wild-type littermates [34]. This is consistent with another study, which found that VSM Grk2 over-expression leads to increased systolic blood pressure (SBP). Moreover, epinephrine injection increased SBP to a greater extent in the VSM-Grk2 over-expressing mice than wild-type control mice [60]. However, cardiac-specific Grk2 expression attenuates Ang II-induced increase in contractility and blood pressure [32], consistent with the pro- and anti-hypertensive effects of GRK2 that are tissue-dependent.

GRK2 expression is increased in animal models of hypertension

The expression of Grk2 mRNA is higher in the aorta but lower in the kidney of spontaneously hypertensive rats (SHRs) than Wistar-Kyoto (WKY) rats [61, 62]. GRK2 protein expressions in lymphocytes and VSMs are also higher in SHRs than Wistar- and WKY rats; vascular GRK2 protein expression is also higher in hypertensive Dahl salt-sensitive than normotensive Dahl salt-resistant rats [63]. The expressions of GRK2 and adrenergic receptors are decreased in the aorta but not in mesenteric arteries of NG-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats, that is accompanied by decreased α1-adrenergic receptor-induced vasoconstriction along with increased β2-adrenergic receptor-mediated vasodilation; these changes are the opposite to those found in the aortas of SHRs [64]. In addition, renal GRK2 expression is increased in L-NAME-induced hypertensive rats. However, renal but not left ventricular GRK2 expression is decreased in SHRs [62].

GRK2 and human hypertension

Studies have shown abnormal GRK2 expression and/or activity in the hypertensive state. GRK activity and GRK2 expression in lymphocytes are increased in hypertensive relative to normotensive humans [14]. The increase in GRK2 protein expression in lymphocytes from hypertensive subjects is positively associated with blood pressure and inversely associated with β-adrenergic agonist-mediated increase in adenylyl cyclase activity [14, 65]. Izzo et al. also reported that GRK2 expression is increased in blood lymphocytes of hypertensive patients and the impaired β-AR-mediated vasorelaxation in the brachial artery is restored by treatment with heparin, a nonspecific GRK inhibitor [66]. Further studies showed that in Black Americans, GRK2 but not GRK5 protein expression is increased 2-fold and GRK activity is increased >40% in the lymphocytes, which correlated with increasing blood pressure [67]. A case-control study in Han Chinese showed that the dominant model (CC vs. CT + TT) of rs1894111 polymorphism in the ADRBK1 (GRK2) gene is associated with low-renin hypertension [68]. In addition, abnormal GRK2 expression or activity is associated with other types of hypertension. For example, elevated GRK2 levels in the umbilical vasculature are associated with elevated blood pressure in subjects with gestational hypertension and preeclampsia [69], but this may be a compensatory rather than a causative effect. Insufficient GRK2 activity compromises spiral artery remodeling and initiates necrotic events in the placenta, thereby causing preeclampsia [70].

GRK3

GRK3 is ubiquitously expressed in mammalian organs and tissues. There are limited studies on the association between GRK3 and hypertension. GRK3 expression in cardiac myocytes progressively increases in 6-, 12-, and 24-month-old spontaneously hypertensive heart failure rats and is significantly higher than in control rats [71]. Grk3 mRNA levels in human lymphocytes are inversely associated with SBP and diastolic blood pressure (DBP) [72], suggesting that GRK3 may play a beneficial role in the regulation of blood pressure. This is, at least in part, supported by findings in transgenic mice. Cardiac myocyte-restricted expression of the carboxyl-terminal fragment of Grk3, a competitive inhibitor of Grk3, results in a phenotype with elevated SBP and DBP but without alterations of heart rate in conscious, unrestrained mice [73]. Further studies found that the cardiomyocyte-restricted inhibition of Grk3 in mice does not alter the hypertrophic response but attenuates cardiac dysfunction and heart failure with chronic pressure overload [74]. It should be noted that some GPCRs that regulate blood pressure, such as dopamine receptors and β-ARs are also regulated by GRK3 [75, 76]. Grk3 expressed in HEK293 cells augments the agonist-induced AT1R or D1R phosphorylation, causing their desensitization [41]. However, the physiological consequences of altered GRK3 expression is unclear. Renal GRK3 expression is not different between WKY rats and SHRs but renal GRK3 mRNA is increased in the kidneys of rats made hypertensive with L-NAME [62]. The role of GRK3 in the regulation of blood pressure needs to be studied further.

GRK4

Effect of GRK4 on blood pressure

GRK4 is expressed to a greater extent in the testes and myometrium and to a lesser extent in other tissues such as the brain and kidney [13]. We also reported its expression in the artery and heart [28, 77], and found that renal and cardiac GRK4 levels are elevated by kidney ischemia-reperfusion injury and myocardial infarction, respectively [27, 28].

The role of GRK4 in the regulation of blood pressure is confirmed in several animal models of hypertension. Global Grk4 knockout mice have lower SBP and DBP than Grk4 wild-type (WT) mice [78]. Selective renal Grk4 knockdown, via chronic renal cortical interstitial-selective infusion of Grk4 antisense oligodeoxynucleotides, increases urine flow and ameliorates the sodium retention and elevated blood pressure of SHRs [79, 80]. We have reported that down-regulation of renal GRK4 expression, via ultrasound-targeted microbubble destruction-delivered Grk4 small interfering RNA (siRNA), decreases blood pressure, accompanied with increased sodium excretion in SHRs [21, 81].

In contrast to the lowering of blood pressure caused by the silencing of Grk4 [78–82], the over-expression of human Grk4 gene variants (hGrk4γ 65L, hGrk4γ 142V, or hGrk4γ 486V) in mice has the opposite effect on blood pressure. On normal salt diet, transgenic mice with over-expression of human GRK4γ (hGRK4γ) variant 142V have higher blood pressure than WT transgenic mice [15, 77, 78, 82]. However, hGrk4γ 486V [83] and hGrk4γ 65L transgenic mice have normal blood pressure on a normal-salt diet but have elevated blood pressure on a high-salt diet, indicating that hGRK4γ 486V and hGRK4γ 65L transgenic mice have salt-sensitive hypertension while hGrk4γ 142V transgenic mice have salt-resistant hypertension.

The reason why different GRK4 variants exhibit different phenotypes in blood pressure regulation is still unknown. Our previous study found that the salt sensitivity of hGRK4γ 486V mice is due, in part, to increased renal reactive oxygen species production, which can be attributed to defective renal antioxidant mechanisms [83]. However, the main reason for the different phenotypes of different GRK4 variants could be due to the different structures of the GRK4 variants. We presume that the polymorphisms alter the structure of GRK4, that modulate its kinase activity, and affect substrate-regulated biological responses that subsequently cause hypertension. Allen et al. reported the overall crystal structure of GRK4α A486V and differences in the structure of GRK4α A486V from other GRKs. They found that relative to WT GRK4α, GRK4α A486V has an increased rate of autophosphorylation of a number of residues, which is due to a defective lag in the absence of preincubation with ATP [84]. However, the mechanism by which different GRK4 polymorphisms affect enzymatic activity needs more investigation in future studies.

The control of blood pressure by GRK4 is due in part to its regulation of renal dopamine receptors. In human renal proximal tubule cells, GRK4 constitutively phosphorylates the D1R, even in the absence of agonist activation, causing its internalization and constitutive desensitization [85]. Treatment with heparin, an inhibitor of GRK activity, or antisense oligonucleotides (GRK4 > GRK2) blunt the agonist-induced D1R desensitization [86]. In human essential hypertension, single nucleotide polymorphisms (SNPs) in GRK4γ increase GRK activity and D1R serine phosphorylation, causing the uncoupling of D1R from its G protein/effector enzyme complex in the renal proximal tubule [15]. GRK4-mediated regulation of D1R expression or activity has been confirmed in several animal models of hypertension. We have reported that GKR4 impairs renal tubular and arterial D1R expression and D1R-mediated sodium excretion and vasodilation in offspring with hypertension related to in utero exposure to some factors such as fine particulate matter, e.g., PM2.5, lipopolysaccharide, and cold stress [87–89]. The impairment of the D1R function as part of the insulin resistance in type 2 diabetes mellitus in mice has also been related to increased GRK4 expression [90]. GRK4 also regulates the phosphorylation and function of the dopamine D3 receptor (D3R) in human proximal tubule cells [91]. However, the role of GRK4 in D3R-mediated regulation of blood pressure remains unclear.

GRK4 can also control blood pressure by interacting with the AT1R. hGrk4γ 142V phosphorylates HDAC1 and promotes its export from the nucleus to the cytoplasm resulting in an increase in the transcription of AT1R, presumably by decreasing its deacetylation [78]. AT1R blockade or the deletion of the Agtr1a gene normalizes hypertension in Grk4γ 142V mice [78]. We have reported that GRK4 is expressed in VSMCs of the aorta. AT1R expression is higher in the aorta of Grk4γ 142V transgenic mice than WT mice. Ang II-mediated vasoconstriction of the aorta is greater in Grk4γ 142V mice than in WT mice [77]. GRK4-positive regulation of AT1R expression and function is also found in other hypertensive animal models, including the male hypertensive offspring of male Sprague-Dawley rats that were exposed to fine particulate matter with an aerodynamic diameter of ≤2.5 μm [92]. We have also recently reported that GRK4 increases the phosphorylation of angiotensin II type 2 receptor (AT2R) which impairs renal AT2R-mediated diuresis and natriuresis, which participate in the GRK4-mediated regulation of blood pressure [93].In addition to dopamine and Ang II receptors, GRK4 also regulates other receptors such as the endothelin type B receptor (ETBR) and AdipoR1. Compared with WT mice, hGRK4γ 142V mice have increased phosphorylation of renal ETBR and AdipoR1 and impaired ETBR- and AdipoR1-induced diuresis and natriuresis [21, 82]. By contrast, renal-selective GRK4 knockdown normalizes the increased ETBR and AdipoR1 phosphorylation, and partially or fully restores the ETBR- and AdipoR1-mediated increase in sodium excretion and reduction of blood pressure in SHRs [21, 82].

GRK4 in hypertensive animal models

Basal GRK4 expression and activity in the kidney and artery are higher in SHRs than in WKY rats [61, 79, 80, 82, 93]. The increased GRK4 expression in the renal and artery in SHRs is organ-specific because there is no difference in cardiac GRK4 expression between WKY and SHRs [79]. Similar results are found in kidneys of humans with essential hypertension. Moreover, the increased activity of GRK4 in the kidneys of hypertensive subjects is caused not by increased renal GRK4 protein expression but rather by constitutively active variants of GRK4 [15]. The role of GRK4 in hypertension is further confirmed by studies involving renal Grk4 depletion, which efficiently reduces GRK4 expression and lowers blood pressure in SHRs, accompanied with increased urine volume and sodium excretion [21, 79–82]. In addition, GRK4 expression and activity in the kidney and artery are increased in other animal models of hypertension [87–89, 94–96].

GRK4 in human essential hypertension

The GRK4 locus on human chromosome 4p16.3 is associated with essential hypertension and salt sensitivity [13]. Several GRK4 gene variants, e.g., R65L, A142V, and A486V, are positively associated with essential hypertension in several ethnic populations [97–110] [Table 2]. However, the association between the GRK4 variants and hypertension was not found in other studies, which may be age/sex/race/ethnicity-related, or a failure to study all the GRK4 variants [103, 109, 111–114]. It should be noted that recent studies reported that some new GRK4 variants are associated with hypertension (GRK4 rs1644731), both hypertension and diabetes (GRK4 rs1557213), or cardiovascular disease risk and diabetes (GRK4 rs60314379) [104, 105, 115]. In addition, an earlier meta-analysis showed that GRK4 rs1024323 is associated with hypertension in Caucasians, but not in East Asians and Africans [106].Table 2 GRK4 variants in hypertensive and normotensive subjects

GRK4 Variant	Ethnic Group	Single or Multilocus Analyses	Clinical Findings	
A142V (rs1024323)	Japanese	Single-locus	Correlates with low-renin hypertension [99]	
	Japanese	Two-locus	The combination of GRK4 A142V and CYP11B2 predicts low-renin essential hypertension [99]	
	Japanese	Multi-locus	The combination of GRK4 A142V, R65L, and A486V predicts salt-sensitive hypertension [99]	
	African- American	Single-locus	Correlates with blood pressure response to metoprolol among hypertensive male subjects [111]	
	Black subjects	Single-locus	Predicts blood pressure response to dietary modification in Black subjects with mild-to-moderate hypertension [169]	
	American	Single-locus	Correlates with increased risk for adverse cardiovascular outcomes [164]	
	Japanese	Single-locus	Correlates with hypertension; Carriers of hGRK4 142V have a greater decrease in SBP in response to ARBs [165]	
	Chinese	Single-locus	Hypertensive subjects with GRK4 A142V are more likely to be non-dippers [166]	
A486V (rs1801058)	Italian	Single-locus	Associates with mild hypertension [102]	
	Euro-Australian	Single-locus	Correlates with hypertension [101]	
	Chinese	Single-locus	Associates with mild hypertension [100]	
	Chinese	Single-locus	Correlates with hypertension [171]	
	African American	Single-locus	Negatively correlates with hypertension in nonobese subjects [112]	
	European	Single-locus	Correlates with salt sensitivity of blood pressure [107]	
	African Brazilian	Two-locus	NOS3-GRK4 interaction is related to DBP levels [98]	
	American	Single-locus	Correlates with increased risk for adverse cardiovascular outcomes [164]	
	Japanese	Single-locus	Correlates with hypertension; Carriers of hGRK4 486V were less to achieve the blood pressure goal in response to an ARB [165]	
	Korean	Single-locus	A high sodium intake increases the obesity risk in children with GRK4 A486V regardless of sex [116]	
	Korean	Multi-locus	A high sodium intake increases the obesity risk in boys with the combination of GRK4 A486V, ACE, and SLC12A3 variants [116]	
	Korean	Two-locus	The combination of GRK4 A486V and CYP11B2 variants increases the obesity risk in girls when sodium intake is increased [116]	
	Chinese	Single-locus	Hypertensive subjects with GRK4 A486V are more likely to be non-dippers [166]	
R65L (rs2960306)	Ghanaian	Two-locus	The combination of GRK4 R65L and ACE predicts the hypertensive phenotype [108]	
	American	Single-locus	Associates with stress-induced reduction in urinary sodium excretion in Black normotensive adolescents [117]	
	Black subject	Single-locus	Predicts positive blood pressure response to dietary modification in Black subjects with mild-to-moderate hypertension [169]	
	American	Single-locus	Correlates with increased risk for adverse cardiovascular outcomes [164]	
	Swiss	Two-locus	Patients with GRK4 65L and 142 V need more antihypertensive treatment to reach the same MAP than homozygous carriers of only 1 variant or heterozygous/wild-type carriers of R65L, A142V, and A486V alleles [168]	
	Korean	Single-locus	The GRK4 65 L TT genotype is inversely correlated with hypertension risk [103]	
	Chinese	Single-locus	Hypertensive subjects with GRK4 R65L are more likely to be non-dippers [166]	
Other GRK4 variants				
 rs2488815	Chinese	Single-locus	Associates with the decreased eGFR [172]	
 rs1419044	American	Single-locus	Correlates with bevacizumab-induced hypertension [173]	
 rs1557213	Chinese	Single-locus	Contributes to the risk of hypertension [105]	
 rs1644731	Chinese	Two-locus	GRK4 rs1644731 and RDH8 rs1801058 are associated with hypertension [104]	
ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, GRK4 G protein-coupled receptor kinase 4, MBP mean arterial blood pressure, NOS3 nitric oxide synthase 3, RDH8 retinol dehydrogenase 8, SBP systolic blood pressure, SLC12A3 solute carrier family 12 member 3

GRK4 variants are also associated with salt sensitivity. In a Japanese cohort, the genotype and allele frequencies of GRK4 SNPs, including R65L, A142V, and A486V, are higher in salt-sensitive than in salt-resistant hypertensive subjects. Sodium excretion was reported to be inversely related to the number of GRK4 variants in hypertensive persons, and the natriuretic response to dopaminergic stimulation is impaired in normotensive persons having three or more GRK4 gene variants [99]. A large genome-wide association study in 15,034 Korean adults investigated the correlation of 1282 candidate SNPs with dietary sodium intake and found that the GRK4 R65L TT genotype is inversely associated with salt-sensitive hypertension risk [103]. Moreover, GRK4 polymorphisms are also associated with salt sensitivity in normotensive subjects [107, 116]. The GRK4 65L allele is associated with impaired renal sodium handling in response to stress in Black normotensive adolescents [117].

GRK5

GRK5 is ubiquitously expressed in mammalian organs and tissues, including the heart, lung, and retina [118]. GRK5 is involved in cardiovascular diseases, including cardiac fibrosis, heart failure, and hypertension [12, 119–124]. GRK5 mRNA and protein levels are increased in the aorta of Ang II- and norepinephrine-induced hypertensive rats [121]. Gkr5 mRNA expression is also increased in the left ventricle and kidney of rats with hypertension induced by L-NAME [62]. However, in this report, the mRNA levels of renal GRK3 and GRK5 are not different between WKY and SHRs [62].

The role of GRK5 in the regulation of blood pressure is verified in transgenic mice. VSM-specific overexpression of Grk5 increases blood pressure, which is sex-modified because male mice with VSM-Grk5 overexpression have a much greater increase in blood pressure (~26 mm Hg, mean arterial pressure) than female Grk5 mice [122]. However, the intracardiac injection of adenovirus that encodes for the RH domain within the amino terminus of Grk5 does not reduce blood pressure levels in SHRs or in WKY rats [123]. It should be noted that the role of GRK5 in the regulation of blood pressure is complicated. Mice with global Grk5 ablation have impaired glucose tolerance and insulin sensitivity compared with their WT littermates [124]. Therefore, GRK5 may be a positive regulator of insulin resistance, which contributes to the pathogenesis of hypertension [125]. In addition, Grk5 overexpression augments the agonist-induced AT1R or D1R phosphorylation, leading to their desensitization; desensitization of AT1R should favor a lower blood pressure while the opposite is true for D1R and therefore, these two effects by themselves may not lead to a change in blood pressure [38, 41]. Cardiac-specific Grk5 expression decreases basal left ventricle systolic pressure, slows left ventricle relaxation, and increases β-AR desensitization, but has no effect on Ang II-induced contractile response [32]. Thus, defining the role of GRK5 in the regulation of blood pressure needs to be studied further.

GRK5 is also associated with other blood pressure regulation-related cardiovascular diseases such as myocardial infarction or cardiometabolic traits such as hyperlipidemia [119, 126]. Grk5 SNPs are also associated with the race-related therapeutic efficacy of some drugs, including β-adrenergic blockers [127, 128].

GRK6

GRK6 is ubiquitously expressed in mammalian organs and tissues, including the heart and intestines [71, 129–131]. There is no direct proof of the role of GRK6 in the regulation of blood pressure. However, there are some reports on the association between GRK6 and hypertension [71]. Compared with control rats, total GRK6 expression is increased, and its distribution is reduced in the intercalated disks but increased in the cytoplasm of cardiac myocytes in spontaneously hypertensive heart failure rats [71]. This may be involved in abnormal remodeling of cardiac myocytes in hypertensive hypertrophy and failure. The cardiomyocytes of GRK6 but not GRK5 knockout mice have an augmented fractional shortening in response to Ang II [132].

Abnormal proliferation of endothelial cells is part of the vascular remodeling in hypertension that may be related to a decrease in vascular endothelial GRK6 expression caused by miR-27a [133]. Cyclic stretching of VSMs, to mimic the pathologically increased stretch in hypertension, causes the transfer of miR-27a via VSMC microparticles to the endothelial cells [133].

As aforementioned, sodium retention, caused by impaired renal sodium excretion, is part of the pathological process in hypertension [134]. An increase in intestinal sodium absorption is also part of the increased sodium balance in hypertension, which may be related to increased activity of NHE3 and Na+-K+-ATPase [135, 136]. Inhibition of GRK6, but not GRK4, prevents the loss of dopamine D1-like receptor-mediated inhibition of Cl/HCO3- exchanger and NHE3 activity in rat intestinal epithelial cells [130, 131]. In addition, GRK6 regulates insulin homeostasis, an abnormality which participates in the pathogenesis of hypertension [137]. GRK6 inhibition increases insulin secretion but reduces insulin processing; Grk6 knockdown reduces cellular insulin levels, and attenuates insulin secretion, but enhances proinsulin secretion consistent with decreased processing [138]. However, the proof of the association between GRK6 and hypertension is still weak and needs further exploration.

Modulation of Grks in the regulation of blood pressure

Most studies have focused on the role of GRKs in the regulation of GPCR expression and activity. However, there are studies reporting on how GRKs are regulated. In fact, there are some studies reporting that GRKs per se are modulated by factors, which subsequently regulate blood pressure. For example, long-term exercise in SHRs, beginning at the prehypertensive stage (four weeks old), improves vascular insulin sensitivity via down-regulation of vascular GRK2, which limits the progression of hypertension [58]. Activation of the TGF-β signaling cascade in VSMCs increases GRK2 expression, consequently inhibiting Ang II-induced VSMC proliferation and migration [139]. We have reported that the expression and activity of GRKs are regulated by several factors, including long-term PM2.5 exposure, prenatal and paternal PM2.5 exposure, in utero lipopolysaccharide or cold stress exposure, and maternal diabetes mellitus [49, 87–89, 92, 94].

The expression of GRKs is regulated by transcription factors and signaling molecules. Others and we have reported that renal GRK4 expression is positively regulated by the activation of the transcription factor c-Myc, which binds to the promoter of Grk4 gene [87, 90, 140]. Other transcription factors, such as Foxo1, NF-κB, and cAMP-responsive element binding protein, are also involved in the regulation of transcription of GRKs (GRK2, GRK5, GRK6) [141–143]. Some key signaling molecules such as protein kinases participate in the modulation of GRK expression. We reported that inhibition of PKC reduces the increased GRK2 expression and normalizes D1R function in renal proximal tubule cells from diabetic mother offspring, which may be beneficial in the treatment of maternal diabetes mellitus-programmed hypertension [49]. Activation of PKC increases GRK2 protein and activity, causing the dysfunction of endothelium-dependent relaxation to insulin in mouse aorta [144]. By contrast, activation of PKC decreases GRK6 promoter activity and expression [143]. Post-transcriptional regulation, including ubiquitination, also plays an important role in the regulation of GRKs [145, 146].

The regulation of GRK activity or cellular location, independent of its expression, is also important in disease states. Insulin or oxidative stress causes renal D1R desensitization and impairs its ability to inhibit Na+-K+-ATPase activity by promoting GRK2 translocation to the plasma membrane [48, 147]. The increased blood pressure of SHRs is caused, in part, by impaired renal D1R function [148], that is due to increased GRK4 activity and sorting nexins (e.g., SNX5 and SNX19) [15, 149, 150]. SNXs play a vital role in receptor trafficking [151]. SNX5 directly interacts with renal GRK4 and inhibits its ability to phosphorylate and desensitize D1R [149].The nuclear translocation of GRK5 participates in fibroblast activation and cardiac fibrosis; Ang II induces the nuclear translocation of cardiac GRK5 [12]. It should be noted that SNPs of GRKs also affect the activity of GRKs. GRK4 variants can increase the activity of GRK4 [28, 77–79, 93]. As aforementioned, increased renal GRK4 activity, caused by GRK4 gene variants, causes hypertension [15, 77, 78, 82, 83]. The GRK4 variant A486V has been shown to increase the impairment of cardiac function after myocardial infarction [28]. A functional GRK2 SNP which inhibits its activity potentiates β-adrenergic receptor-mediated cAMP accumulation and potentially can be used in the treatment of heart failure [152].

Grks and treatment of hypertension

GRK inhibition

Because GRKs play a role in the pathogenesis of cardiovascular diseases, including hypertension, many studies have focused on searching selective inhibitors of GRKs, especially GRK2 and GRK5. Some existing drugs have been verified as potential GRK2 inhibitors. For example, paroxetine directly inhibits the activity of GRK2 by binding its active site which stabilizes the kinase domain [153]. In hypertension, paroxetine increases β1-AR sensitivity and attenuates cardiac hypertrophy by blocking the interaction between GRK2 and β1-AR [154]. The actions of some GRK inhibitors have been related to their crystal structure. For example, based on the conformation of the HJ loop within the X-ray structure of GRK2, cyclic peptide 7 was found to suppress selectively and potently GRK2 activity [155]. The pharmacological inhibition of GRK2 by a cyclic peptide C7 improves cardiac metabolism and function in experimental heart failure [156]. Small molecule GRK inhibitors, including paroxetine, Takeda compound 101, and CCG224063, attenuate GRK2-mediated desensitization of vasoconstrictor-induced arterial contractions, highlighting a potential strategy for blood pressure regulation by targeting GRK2 function [157].

Most of the current studies on the inhibition of GRK function have focused on the direct interaction between the inhibitor and the kinase domain of the protein. However, inhibitors of the RH domain of GRK2 have also been reported to reduce the RH-mediated receptor desensitization and GRK2 translocation to the plasma membrane [158, 159]. These novel inhibitors of phosphorylation-independent actions of GRK2 provide new strategies for the development of innovative pharmacologic therapy for hypertension.

Some studies have also explored the possibility of simultaneous inhibition of two types of GRKs by one inhibitor. For example, analyses of the structures and chemical properties of key residues in the protein crystal structures of GRK2 and GRK5 have determined the specific amino acid distribution within the GRK2/GRK5 target site [160, 161]. CCG215022, a GRK2 inhibitor, has nanomolar IC50 values against both GRK2 and GRK5. A 2.4 Å crystal structure of the GRK5·CCG215022 complex revealed that the inhibitor binds in the active site similarly to its parent compound [162]. The structure and function of GRK4 486V have also been reported; Ser-485 in the kinase C-tail is one of the residues that is responsible for the increased rate of autophosphorylation of GRK4 486V [84]. These are promising reports on the generation of selective GRK inhibitors in the treatment of hypertension.

GRKs and pharmacogenomics of hypertension

Over the past decade, pharmacogenetics has been used to guide cardiovascular drug therapy [163]. The gene variants of GRKs may be important to guide antihypertensive strategies. The African American Study of Kidney Disease and Hypertension Study showed that in African-American men, but not women, the response to the β1-AR blocker metoprolol was more rapid in carriers of GRK4 142V than carriers of GRK4 A142 but the response was decreased in the presence of GRK4 65L [111]. The Pharmacogenomic Evaluation of Antihypertensive Responses trial showed that the response of hypertensive patients to β-blockers is influenced by GRK4 variants. In African-Americans and Caucasians, increasing number of copies of the GRK4 variant 65L-142V haplotype is associated with reduced response to β-blocker monotherapy with atenolol [164]. Moreover, all three GRK4 variants (65L, 142V, and 486V) are associated with increased risk for the primary outcome of first occurrence of all cause death, nonfatal myocardial infarction, or nonfatal stroke in American whites and Hispanics [164]. Another study in hypertensive Japanese showed that patients with hGRK4 142V have a greater decrease in SBP in response to angiotensin receptor blockers (ARBs) than non-carrier subjects. However, those with GRK4 486V are less likely to achieve the blood pressure goal in response to ARBs than those without GRK4 variants [165]. Our study also found that non-dipper circadian rhythm is positively associated with the presence of GRK4 variants. Moreover, patients with these three GRK4 variants have a better antihypertensive response to candesartan, an ARB, than those with GRK4 WT gene [166].

Regarding the antihypertensive effect of diuretics, one study showed that subjects with more than three GRK4 gene variants (A142V, A486V, and R65L) have a greater increase in potassium and sodium excretion in response to hydrochlorothiazide than those with three or less than three GRK4 gene variants [167]. In another study, hypertensive subjects with GRK4 65L and 142V needed more antihypertensive therapy, especially diuretics, to reach the same mean arterial pressure as did the heterozygous and wild-type carriers of GRK4 [168]. Other GRK variants are reported to be associated with therapeutic effect of antihypertensive drugs. African-American carriers of GRK2 rs4930416 have a greater decrease in both SBP and DBP in response to hydrochlorothiazide while European-Americans with GRK2 rs1894111 have a greater decrease in both SBP and DBP in response to hydrochlorothiazide [16]. African-American or European-American carriers of GRK5Gln41, relative to homozygous carriers of GRK5Leu41, do not respond differently to hydrochlorothiazide or atenolol but those with GRK5Leu41 have a 46.5% risk reduction for adverse cardiovascular outcomes compared with GRK5 Gln41 homozygotes, independent of treatment [16].

GRK4 variants are also associated with the blood pressure response to lifestyle modification. For example, Rayner et al. found that in South African Blacks 50-75 years old with mild-to-moderate hypertension, GRK4 polymorphisms, A142V and R65L, can predict blood pressure response to dietary reduction of dietary salt intake. Hypertensive subjects with wild-type GRK4 A142 and GRK4 R65 or heterozygous GRK4 A142V and GRK4 R65L but no homozygous GRK4 142V and GRK4 65L have a reduction in their blood pressures in response to a low salt diet [169].

Limitations of Grks research

There are several limitations in the current GRK research. First, there are only a few reports using organ-specific knockout or overexpression GRK mice, which are better to study the role of GRKs in the regulation of blood pressure. Second, the mechanism by which different GRKs polymorphisms affect enzymatic activity remains still unknown, which may be related with the crystal structure of GRKs polymorphisms. Especially, the reason why different GRK4 variants exhibit different salt-sensitive phenotypes in blood pressure regulation needs to be studied in the future. Third, GRK2-mediated effects in the regulation of blood pressure is complicated, and its role in hypertension needs to be clarified more clearly. Fourth, the regulatory mechanisms of GRK remain unclear.

Conclusions

In summary, increasing pieces of evidence demonstrate that GRKs, by regulating different substrates, play important roles in the regulation of blood pressure. Various genetically modified animal models confirm the key role of GRKs in the regulation of blood pressure (Table 3). Aberrant expression and/or activity of GRKs in the cardiovascular system and kidney participate in the pathogenesis of hypertension. Genetic association studies have found associations between GRK gene variants and hypertension. Moreover, individual GRK variants also affect the response to antihypertensive treatment. Increased understanding of the role of GRKs in the regulation of blood pressure may provide novel insights into the pathogenesis of hypertension and new strategies for the prevention and treatment of hypertension.Table 3 Effects of GRK modification on blood pressure and related substrates

GRK isoform	GRK Modification	Mouse Phenotype	Regulation on Substrate and Its Functions	
GRK2	VSM-targeted overexpression	Increases resting SBP, DBP and MAP [34]; increases SBP but not MAP or DBP [60]	Attenuates β-AR signaling and vasodilation, increases aortic medial VSM thickness, and causes cardiac hypertrophy [34]; impairs β-AR signaling in VSM [60]	
	Global adult hemizygous mice (GRK2+/-)	No change in basal SBP, but reduced Ang II-induced hypertension	Increases aortic vasoconstrictor responses to phenylephrine and ET-1 but not to Ang II; increases endothelium-dependent vasodilator responses and NO release; prevents Ang II-induced vascular remodeling [31]	
	Global knockdown Grk2 using shRNA	Causes hypertension [33, 43]	Increases phenylephrine-induced hypertension and contractile response of mesenteric arteries and isoproterenol-mediated vasodilation in phenylephrine pre-constricted mesenteric arteries; decreases desensitization of β-AR signaling in VSMCs [33]; decreases kidney size, nephrogenesis and glomerular count, and glomerular filtration; increases RAS activity and renin- and AT1R-mediated ROS production; does not affect renal AT1R expression [43]	
	GRK2ct or VSM-selective Grk2 ablation	no effect on basal blood pressure; does not prevent 2K1C hypertension [39]	Increases β-AR mediated dilation and α1D-AR stimulated vasoconstriction [39]	
	Selective deletion of endothelial Grk2	not mentioned	Impairs α1-AR-, serotonin-, oxytocin-, and KCl-induced aortic vasoconstriction; increases aortic inflammation, degeneration, and mitochondrial ROS production [59]	
	Grk2 knockdown using siRNA	not mentioned	Improves insulin-induced vasodilation of mesenteric arteries in SHRs [58]	
GRK3	Cardiac-restricted expression of a peptide inhibitor of GRK3 in mice	Increases SBP, DBP, and cardiac output	Does not affect cardiac β-AR responsiveness; increases α1-AR but not β-AR -induced cardiac hypertrophy [73]; attenuates cardiac dysfunction and heart failure after chronic pressure overload [74]	
GRK4	Global Grk4 knockout	Decreases SBP and DBP	Cardiac and renal function not studied [78]	
	Renal depletion using As-Odns	Attenuates SBP and MAP in SHRs [79]	Decreases renal D1R phosphorylation, increases sodium excretion and urine volume, and reduces protein excretion in SHRs [79]	
	UTMD-targeted renal depletion of Grk in rodents	Reduces SBP [81]	Reduces the phosphorylation of some receptors expressed in the kidney (D1R, adipoR1, ETBR, AT2R) and improves receptor-mediated natriuresis and diuresis [21, 81, 82, 93]	
	Overexpression of human GRK4γ 142V in mice	Causes hypertension (normal-salt diet); increases systolic blood pressure in response to Ang II [77]	Impairs renal receptor (D1R, adipoR1, ETBR, AT2R and CCKBR)-mediated sodium excretion [15, 21, 81, 82, 93, 170]; increases arterial AT1R expression and -mediated vasoconstriction [77]; increases renal AT1R expression and -induced sodium retention [78]	
	Overexpression of human GRK4 γ 486V in mice	Salt-sensitive hypertension [83]	Impairs sodium excretion and increases renal oxidative stress [83]; increases renal AT1R expression and activity [83]	
	Overexpression of human GRK4 65L in mice	Salt-sensitive hypertension	Increases D1R phosphorylation [174], increases renal Na+,K+/ATPase and α-ENaC expressions [175]	
GRK5	VSM-specific Overexpression in mice	Causes hypertension; increases MAP to a greater extent in male than female mice	Increases norepinephrine-mediated vasoconstriction in male mice; Decreases βAR-mediated vasodilation and increases Ang II–stimulated vasoconstriction in female but not male mice [122]	
	AdGRK5-NT in rats	Does not affect the blood pressures of WKY and SHRs [123]	Decreases cardiac mass in SHRs and prevents the development of phenylephrine-induced left cardiac hypertrophy, inhibits NF-κB signaling, transcriptional activity and cardiac fibrosis and apoptosis [123]	
	Global knockout mice	Not mentioned	Decreases insulin sensitivity [124]	
GRK6	Global knockout mice	Not mentioned	Causes striatal D2-like receptor supersensitivity [176]

Increases ear inflammation [177]

	
α-AR α-adrenergic receptor, AdGRK5-NT an adenovirus that encodes for the RH domain within the amino terminal of GRK5, adipoR1 adiponectin receptor 1, α-ENaC α-epithelial sodium channel, Ang II angiotensin II, As-Odns antisense oligodeoxynucleotides, AT1R angiotensin II type 1 receptor, AT2R angiotensin II type 2 receptor, β-AR β-adrenergic receptor, ct carboxyterminal, CCKBR cholecystokinin receptor type B, D1R dopamine D1 receptor, DBP diastolic blood pressure, ET-1 endothelin-1, ETBR endothelin receptor type B, GRK G protein-coupled receptor kinase, GRK2ct a peptide inhibitor composed of the carboxyl-terminal portion of GRK2, 2K1C two-kidney one-clip, KCl potassium chloride, MAP mean arterial blood pressure, NF-κB nuclear factor-κB, NO nitric oxide, RAS renin-angiotensin system, ROS reactive oxygen species, SBP systolic blood pressure, ShRNA small hairpin RNA, SHRs spontaneously hypertensive rats, siRNA small interfering RNA, VSM vascular smooth muscle, VSMCs vascular smooth muscle cells, UTMD ultrasound-targeted microbubble destruction

Funding

This work was supported in part by grants from National Natural Science Foundation of China (82070442, 82370435), Program of Chongqing Medical University for Youth Innovation in Future Medicine (W0085), Project of Chongqing Medical Talent Studio (2022), Natural Science Foundation Project of Chongqing (2023NSCQ-MSX1358), Key Program of The Third Affiliated Hospital of Chongqing Medical University (KY22037), and the National Institutes of Health (P01HL074940, DK039308, DK119652, and DK134574).

Compliance with ethical standards

Conflict of interest

PAJ, who is the Scientific Director of Hypogen, Inc., owns US Patent Number 6660474B1 for GRK4. The other authors report no conflicts.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Brouwers S Sudano I Kokubo Y Sulaica EM Arterial hypertension Lancet 2021 398 249 61 10.1016/S0140-6736(21)00221-X 34019821
Brouwers S, Sudano I, Kokubo Y, Sulaica EM. Arterial hypertension. Lancet. 2021;398:249–61.34019821 10.1016/S0140-6736(21)00221-X
2. NCD Risk Factor Collaboration (NCD-RisC Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants Lancet 2021 398 957 80 10.1016/S0140-6736(21)01330-1 34450083
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–80.34450083 10.1016/S0140-6736(21)01330-1
3. Tsao CW Aday AW Almarzooq ZI Anderson CAM Arora P Avery CL Heart disease and stroke statistics-2023 update: a report from the American Heart Association Circulation 2023 147 e93 e621 10.1161/CIR.0000000000001123 36695182
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147:e93–e621.36695182 10.1161/CIR.0000000000001123
4. Carey RM Moran AE Whelton PK Treatment of hypertension: a review JAMA 2022 328 1849 61 10.1001/jama.2022.19590 36346411
Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. 2022;328:1849–61.36346411 10.1001/jama.2022.19590
5. Grogan A Lucero EY Jiang H Rockman HA Pathophysiology and pharmacology of G protein-coupled receptors in the heart Cardiovasc Res 2023 119 1117 29 10.1093/cvr/cvac171 36534965
Grogan A, Lucero EY, Jiang H, Rockman HA. Pathophysiology and pharmacology of G protein-coupled receptors in the heart. Cardiovasc Res. 2023;119:1117–29.36534965 10.1093/cvr/cvac171
6. Jiang H Galtes D Wang J Rockman HA G protein-coupled receptor signaling: transducers and effectors Am J Physiol Cell Physiol 2022 323 C731 C748 10.1152/ajpcell.00210.2022 35816644
Jiang H, Galtes D, Wang J, Rockman HA. G protein-coupled receptor signaling: transducers and effectors. Am J Physiol Cell Physiol. 2022;323:C731–C748.35816644 10.1152/ajpcell.00210.2022
7. Vaz de Castro PAS Jose PA Simões E Silva AC Interactions between the intrarenal dopaminergic and the renin-angiotensin systems in the control of systemic arterial pressure Clin Sci (Lond) 2022 136 1205 27 10.1042/CS20220338 35979889
Vaz de Castro PAS, Jose PA, Simões E Silva AC. Interactions between the intrarenal dopaminergic and the renin-angiotensin systems in the control of systemic arterial pressure. Clin Sci (Lond). 2022;136:1205–27.35979889 10.1042/CS20220338
8. Yang J Villar VAM Jose PA Zeng C Renal dopamine receptors and oxidative stress: role in hypertension Antioxid Redox Signal 2021 34 716 35 10.1089/ars.2020.8106 32349533
Yang J, Villar VAM, Jose PA, Zeng C. Renal dopamine receptors and oxidative stress: role in hypertension. Antioxid Redox Signal. 2021;34:716–35.32349533 10.1089/ars.2020.8106
9. Banday AA Lokhandwala MF Transcriptional regulation of renal dopamine D1 receptor function during oxidative stress Hypertension 2015 65 1064 72 10.1161/HYPERTENSIONAHA.115.05255 25733244
Banday AA, Lokhandwala MF. Transcriptional regulation of renal dopamine D1 receptor function during oxidative stress. Hypertension. 2015;65:1064–72.25733244 10.1161/HYPERTENSIONAHA.115.05255
10. Kemp BA Howell NL Gildea JJ Keller SR Brautigan DL Carey RM 2 receptors mediate natriuresis via protein phosphatase PP2A Circ Res 2022 130 96 111 10.1161/CIRCRESAHA.121.319519 34794320
Kemp BA, Howell NL, Gildea JJ, Keller SR, Brautigan DL, Carey RM, et al. 2 receptors mediate natriuresis via protein phosphatase PP2A. Circ Res. 2022;130:96–111.34794320 10.1161/CIRCRESAHA.121.319519
11. Pfleger J Gresham K Koch WJ G protein-coupled receptor kinases as therapeutic targets in the heart Nat Rev Cardiol 2019 16 612 22 10.1038/s41569-019-0220-3 31186538
Pfleger J, Gresham K, Koch WJ. G protein-coupled receptor kinases as therapeutic targets in the heart. Nat Rev Cardiol. 2019;16:612–22.31186538 10.1038/s41569-019-0220-3
12. Eguchi A Coleman R Gresham K Gao E Ibetti J Chuprun JK GRK5 is a regulator of fibroblast activation and cardiac fibrosis Proc Natl Acad Sci USA 2021 118 e2012854118 10.1073/pnas.2012854118 33500351
Eguchi A, Coleman R, Gresham K, Gao E, Ibetti J, Chuprun JK, et al. GRK5 is a regulator of fibroblast activation and cardiac fibrosis. Proc Natl Acad Sci USA. 2021;118:e2012854118.33500351 10.1073/pnas.2012854118
13. Yang J Hall JE Jose PA Chen K Zeng C Comprehensive insights in GRK4 and hypertension: from mechanisms to potential therapeutics Pharm Ther 2022 239 108194 10.1016/j.pharmthera.2022.108194
Yang J, Hall JE, Jose PA, Chen K, Zeng C. Comprehensive insights in GRK4 and hypertension: from mechanisms to potential therapeutics. Pharm Ther. 2022;239:108194.10.1016/j.pharmthera.2022.108194
14. Gros R Benovic JL Tan CM Feldman RD G-protein-coupled receptor kinase activity is increased in hypertension J Clin Investig 1997 99 2087 93 10.1172/JCI119381 9151780
Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Investig. 1997;99:2087–93.9151780 10.1172/JCI119381
15. Felder RA Sanada H Xu J Yu PY Wang Z Watanabe H G protein-coupled receptor kinase 4 gene variants in human essential hypertension Proc Natl Acad Sci USA 2002 99 3872 7 10.1073/pnas.062694599 11904438
Felder RA, Sanada H, Xu J, Yu PY, Wang Z, Watanabe H, et al. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci USA. 2002;99:3872–7.11904438 10.1073/pnas.062694599
16. Lobmeyer MT Wang L Zineh I Turner ST Gums JG Chapman AB Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients Pharmacogenet Genom 2011 21 42 49 10.1097/FPC.0b013e328341e911
Lobmeyer MT, Wang L, Zineh I, Turner ST, Gums JG, Chapman AB, et al. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genom. 2011;21:42–49.10.1097/FPC.0b013e328341e911
17. Yang J Villar VA Armando I Jose PA Zeng C G protein-coupled receptor kinases: crucial regulators of blood pressure J Am Heart Assoc 2016 5 e003519 10.1161/JAHA.116.003519 27390269
Yang J, Villar VA, Armando I, Jose PA, Zeng C. G protein-coupled receptor kinases: crucial regulators of blood pressure. J Am Heart Assoc. 2016;5:e003519.27390269 10.1161/JAHA.116.003519
18. Sulon SM Benovic JL Targeting G protein-coupled receptor kinases (GRKs) to G protein-coupled receptors Curr Opin Endocr Metab Res 2021 16 56 65 10.1016/j.coemr.2020.09.002 33718657
Sulon SM, Benovic JL, Targeting G. protein-coupled receptor kinases (GRKs) to G protein-coupled receptors. Curr Opin Endocr Metab Res. 2021;16:56–65.33718657 10.1016/j.coemr.2020.09.002
19. Benovic JL Historical perspective of the G protein-coupled receptor kinase family Cells 2021 10 555 10.3390/cells10030555 33806476
Benovic JL. Historical perspective of the G protein-coupled receptor kinase family. Cells. 2021;10:555.33806476 10.3390/cells10030555
20. Chaudhary PK Kim S The GRKs reactome: role in cell biology and pathology Int J Mol Sci 2021 22 3375 10.3390/ijms22073375 33806057
Chaudhary PK, Kim S. The GRKs reactome: role in cell biology and pathology. Int J Mol Sci. 2021;22:3375.33806057 10.3390/ijms22073375
21. Zhang Y Wang S Huang H Zeng A Han Y Zeng C GRK4-mediated adiponectin receptor-1 phosphorylative desensitization as a novel mechanism of reduced renal sodium excretion in hypertension Clin Sci 2020 134 2453 67 10.1042/CS20200671
Zhang Y, Wang S, Huang H, Zeng A, Han Y, Zeng C, et al. GRK4-mediated adiponectin receptor-1 phosphorylative desensitization as a novel mechanism of reduced renal sodium excretion in hypertension. Clin Sci. 2020;134:2453–67.10.1042/CS20200671
22. Crudden C Shibano T Song D Dragomir MP Cismas S Serly J Inhibition of G protein-coupled receptor kinase 2 promotes unbiased downregulation of IGF1 receptor and restrains malignant cell growth Cancer Res 2021 81 501 14 10.1158/0008-5472.CAN-20-1662 33158816
Crudden C, Shibano T, Song D, Dragomir MP, Cismas S, Serly J, et al. Inhibition of G protein-coupled receptor kinase 2 promotes unbiased downregulation of IGF1 receptor and restrains malignant cell growth. Cancer Res. 2021;81:501–14.33158816 10.1158/0008-5472.CAN-20-1662
23. Usui I Imamura T Babendure JL Satoh H Lu JC Hupfeld CJ G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both G alpha q/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes Mol Endocrinol 2005 19 2760 8 10.1210/me.2004-0429 15994203
Usui I, Imamura T, Babendure JL, Satoh H, Lu JC, Hupfeld CJ, et al. G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both G alpha q/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol Endocrinol. 2005;19:2760–8.15994203 10.1210/me.2004-0429
24. Martini JS Raake P Vinge LE DeGeorge BR Jr Chuprun JK Harris DM Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes Proc Natl Acad Sci USA 2008 105 12457 62 10.1073/pnas.0803153105 18711143
Martini JS, Raake P, Vinge LE, DeGeorge BR Jr, Chuprun JK, Harris DM, et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci USA. 2008;105:12457–62.18711143 10.1073/pnas.0803153105
25. Patial S Luo J Porter KJ Benovic JL Parameswaran N G-protein-coupled-receptor kinases mediate TNFα-induced NFκB signalling via direct interaction with and phosphorylation of IκBα Biochem J 2009 425 169 78 10.1042/BJ20090908 19796012
Patial S, Luo J, Porter KJ, Benovic JL, Parameswaran N. G-protein-coupled-receptor kinases mediate TNFα-induced NFκB signalling via direct interaction with and phosphorylation of IκBα. Biochem J. 2009;425:169–78.19796012 10.1042/BJ20090908
26. Gurevich EV Tesmer JJ Mushegian A Gurevich VV G protein-coupled receptor kinases: more than just kinases and not only for GPCRs Pharm Ther 2012 133 40 69 10.1016/j.pharmthera.2011.08.001
Gurevich EV, Tesmer JJ, Mushegian A, Gurevich VV. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharm Ther. 2012;133:40–69.10.1016/j.pharmthera.2011.08.001
27. Yang D Tang M Zhang M Ren H Li X Zhang Z Downregulation of G protein-coupled receptor kinase 4 protects against kidney ischemia-reperfusion injury Kidney Int 2023 103 719 34 10.1016/j.kint.2022.12.023 36669643
Yang D, Tang M, Zhang M, Ren H, Li X, Zhang Z, et al. Downregulation of G protein-coupled receptor kinase 4 protects against kidney ischemia-reperfusion injury. Kidney Int. 2023;103:719–34.36669643 10.1016/j.kint.2022.12.023
28. Li L Fu W Gong X Chen Z Tang L Yang D The role of G protein-coupled receptor kinase 4 in cardiomyocyte injury after myocardial infarction Eur Heart J 2021 42 1415 30 10.1093/eurheartj/ehaa878 33280021
Li L, Fu W, Gong X, Chen Z, Tang L, Yang D, et al. The role of G protein-coupled receptor kinase 4 in cardiomyocyte injury after myocardial infarction. Eur Heart J. 2021;42:1415–30.33280021 10.1093/eurheartj/ehaa878
29. Gerhards J Maerz LD Matthees ESF Donow C Moepps B Premont RT Kinase activity is not required for G protein-coupled receptor kinase 4 restraining mTOR signaling during cilia and kidney development J Am Soc Nephrol 2023 34 590 606 10.1681/ASN.0000000000000082 36810260
Gerhards J, Maerz LD, Matthees ESF, Donow C, Moepps B, Premont RT, et al. Kinase activity is not required for G protein-coupled receptor kinase 4 restraining mTOR signaling during cilia and kidney development. J Am Soc Nephrol. 2023;34:590–606.36810260 10.1681/ASN.0000000000000082
30. Yang J Villar VA Jones JE Jose PA Zeng C G protein-coupled receptor kinase 4: role in hypertension Hypertension 2015 65 1148 55 10.1161/HYPERTENSIONAHA.115.05189 25870190
Yang J, Villar VA, Jones JE, Jose PA, Zeng C. G protein-coupled receptor kinase 4: role in hypertension. Hypertension. 2015;65:1148–55.25870190 10.1161/HYPERTENSIONAHA.115.05189
31. Avendaño MS Lucas E Jurado-Pueyo M Martínez-Revelles S Vila-Bedmar R Mayor F Jr Increased nitric oxide bioavailability in adult GRK2 hemizygous mice protects against angiotensin II-induced hypertension Hypertension. 2014 63 369 75 10.1161/HYPERTENSIONAHA.113.01991 24191280
Avendaño MS, Lucas E, Jurado-Pueyo M, Martínez-Revelles S, Vila-Bedmar R, Mayor F Jr, et al. Increased nitric oxide bioavailability in adult GRK2 hemizygous mice protects against angiotensin II-induced hypertension. Hypertension. 2014;63:369–75.24191280 10.1161/HYPERTENSIONAHA.113.01991
32. Rockman HA Choi DJ Rahman NU Akhter SA Lefkowitz RJ Koch WJ Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice Proc Natl Acad Sci USA 1996 93 9954 9 10.1073/pnas.93.18.9954 8790438
Rockman HA, Choi DJ, Rahman NU, Akhter SA, Lefkowitz RJ, Koch WJ. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA. 1996;93:9954–9.8790438 10.1073/pnas.93.18.9954
33. Tutunea-Fatan E Caetano FA Gros R Ferguson SSG GRK2 targeted knock-down results in spontaneous hypertension, and altered vascular GPCR signaling J Biol Chem 2015 290 5141 55 10.1074/jbc.M114.615658 25561731
Tutunea-Fatan E, Caetano FA, Gros R, Ferguson SSG. GRK2 targeted knock-down results in spontaneous hypertension, and altered vascular GPCR signaling. J Biol Chem. 2015;290:5141–55.25561731 10.1074/jbc.M114.615658
34. Eckhart AD Ozaki T Tevaearai H Rockman HA Koch WJ Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure Mol Pharm 2002 61 749 58 10.1124/mol.61.4.749
Eckhart AD, Ozaki T, Tevaearai H, Rockman HA, Koch WJ. Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharm. 2002;61:749–58.10.1124/mol.61.4.749
35. Morris GE Nelson CP Standen NB Challiss RA Willets JM Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2 Cardiovasc Res 2010 85 424 33 10.1093/cvr/cvp310 19748906
Morris GE, Nelson CP, Standen NB, Challiss RA, Willets JM. Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2. Cardiovasc Res. 2010;85:424–33.19748906 10.1093/cvr/cvp310
36. Morris GE Nelson CP Everitt D Brighton PJ Standen NB Challiss RA G protein-coupled receptor kinase 2 and arrestin2 regulate arterial smooth muscle P2Y-purinoceptor signalling Cardiovasc Res 2011 89 193 203 10.1093/cvr/cvq249 20705669
Morris GE, Nelson CP, Everitt D, Brighton PJ, Standen NB, Challiss RA, et al. G protein-coupled receptor kinase 2 and arrestin2 regulate arterial smooth muscle P2Y-purinoceptor signalling. Cardiovasc Res. 2011;89:193–203.20705669 10.1093/cvr/cvq249
37. Morris GE Nelson CP Brighton PJ Standen NB Challiss RA Willets JM Arrestins 2 and 3 differentially regulate ETA and P2Y2 receptor-mediated cell signaling and migration in arterial smooth muscle Am J Physiol Cell Physiol 2012 302 C723 C734 10.1152/ajpcell.00202.2011 22159081
Morris GE, Nelson CP, Brighton PJ, Standen NB, Challiss RA, Willets JM. Arrestins 2 and 3 differentially regulate ETA and P2Y2 receptor-mediated cell signaling and migration in arterial smooth muscle. Am J Physiol Cell Physiol. 2012;302:C723–C734.22159081 10.1152/ajpcell.00202.2011
38. Oppermann M Freedman NJ Alexander RW Lefkowitz RJ Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C J Biol Chem 1996 271 13266 72 10.1074/jbc.271.22.13266 8662816
Oppermann M, Freedman NJ, Alexander RW, Lefkowitz RJ. Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C. J Biol Chem. 1996;271:13266–72.8662816 10.1074/jbc.271.22.13266
39. Cohn HI Harris DM Pesant S Pfeiffer M Zhou RH Koch WJ Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances alpha1D-adrenergic receptor constriction Am J Physiol Heart Circ Physiol 2008 295 H1695 H1704 10.1152/ajpheart.00564.2008 18723764
Cohn HI, Harris DM, Pesant S, Pfeiffer M, Zhou RH, Koch WJ, et al. Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances alpha1D-adrenergic receptor constriction. Am J Physiol Heart Circ Physiol. 2008;295:H1695–H1704.18723764 10.1152/ajpheart.00564.2008
40. Nash CA Nelson CP Mistry R Moeller-Olsen C Christofidou E Challiss RAJ Differential regulation of β2-adrenoceptor and adenosine A2B receptor signalling by GRK and arrestin proteins in arterial smooth muscle Cell Signal 2018 51 86 98 10.1016/j.cellsig.2018.07.013 30075183
Nash CA, Nelson CP, Mistry R, Moeller-Olsen C, Christofidou E, Challiss RAJ, et al. Differential regulation of β2-adrenoceptor and adenosine A2B receptor signalling by GRK and arrestin proteins in arterial smooth muscle. Cell Signal. 2018;51:86–98.30075183 10.1016/j.cellsig.2018.07.013
41. Tiberi M Nash SR Bertrand L Lefkowitz RJ Caron MG Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases J Biol Chem 1996 271 3771 8 10.1074/jbc.271.7.3771 8631993
Tiberi M, Nash SR, Bertrand L, Lefkowitz RJ, Caron MG. Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases. J Biol Chem. 1996;271:3771–8.8631993 10.1074/jbc.271.7.3771
42. Taguchi K Bessho N Hasegawa M Narimatsu H Matsumoto T Kobayashi T Co-treatment with clonidine and a GRK2 inhibitor prevented rebound hypertension and endothelial dysfunction after withdrawal in diabetes Hypertens Res 2018 41 263 74 10.1038/s41440-018-0016-6 29463871
Taguchi K, Bessho N, Hasegawa M, Narimatsu H, Matsumoto T, Kobayashi T. Co-treatment with clonidine and a GRK2 inhibitor prevented rebound hypertension and endothelial dysfunction after withdrawal in diabetes. Hypertens Res. 2018;41:263–74.29463871 10.1038/s41440-018-0016-6
43. Tutunea-Fatan E Abd-Elrahman KS Thibodeau JF Holterman CE Holleran BJ Leduc R GRK2 knockdown in mice exacerbates kidney injury and alters renal mechanisms of blood pressure regulation Sci Rep 2018 8 11415 10.1038/s41598-018-29876-8 30061705
Tutunea-Fatan E, Abd-Elrahman KS, Thibodeau JF, Holterman CE, Holleran BJ, Leduc R, et al. GRK2 knockdown in mice exacerbates kidney injury and alters renal mechanisms of blood pressure regulation. Sci Rep. 2018;8:11415.30061705 10.1038/s41598-018-29876-8
44. Dinudom A Fotia AB Lefkowitz RJ Young JA Kumar S Cook DI The kinase Grk2 regulates Nedd4/Nedd4-2-dependent control of epithelial Na+ channels Proc Natl Acad Sci USA 2004 101 11886 90 10.1073/pnas.0402178101 15284439
Dinudom A, Fotia AB, Lefkowitz RJ, Young JA, Kumar S, Cook DI. The kinase Grk2 regulates Nedd4/Nedd4-2-dependent control of epithelial Na+ channels. Proc Natl Acad Sci USA. 2004;101:11886–90.15284439 10.1073/pnas.0402178101
45. Pitzer AL Van Beusecum JP Kleyman TR Kirabo A ENaC in salt-sensitive hypertension: kidney and beyond Curr Hypertens Rep 2020 22 69 10.1007/s11906-020-01067-9 32852643
Pitzer AL, Van Beusecum JP, Kleyman TR, Kirabo A. ENaC in salt-sensitive hypertension: kidney and beyond. Curr Hypertens Rep. 2020;22:69.32852643 10.1007/s11906-020-01067-9
46. Sanchez-Perez A Kumar S Cook DI GRK2 interacts with and phosphorylates Nedd4 and Nedd4-2 Biochem Biophys Res Commun 2007 359 611 5 10.1016/j.bbrc.2007.05.134 17544362
Sanchez-Perez A, Kumar S, Cook DI. GRK2 interacts with and phosphorylates Nedd4 and Nedd4-2. Biochem Biophys Res Commun. 2007;359:611–5.17544362 10.1016/j.bbrc.2007.05.134
47. Asghar M Banday AA Fardoun RZ Lokhandwala MF Hydrogen peroxide causes uncoupling of dopamine D1-like receptors from G proteins via a mechanism involving protein kinase C and G-protein-coupled receptor kinase 2 Free Radic Biol Med 2006 40 13 20 10.1016/j.freeradbiomed.2005.08.018 16337875
Asghar M, Banday AA, Fardoun RZ, Lokhandwala MF. Hydrogen peroxide causes uncoupling of dopamine D1-like receptors from G proteins via a mechanism involving protein kinase C and G-protein-coupled receptor kinase 2. Free Radic Biol Med. 2006;40:13–20.16337875 10.1016/j.freeradbiomed.2005.08.018
48. Banday AA Fazili FR Lokhandwala MF Insulin causes renal dopamine D1 receptor desensitization via GRK2-mediated receptor phosphorylation involving phosphatidylinositol 3-kinase and protein kinase C Am J Physiol Ren Physiol 2007 293 F877 F884 10.1152/ajprenal.00184.2007
Banday AA, Fazili FR, Lokhandwala MF. Insulin causes renal dopamine D1 receptor desensitization via GRK2-mediated receptor phosphorylation involving phosphatidylinositol 3-kinase and protein kinase C. Am J Physiol Ren Physiol. 2007;293:F877–F884.10.1152/ajprenal.00184.2007
49. Luo H Chen C Guo L Xu Z Peng X Wang X Exposure to maternal diabetes mellitus causes renal dopamine D1 receptor dysfunction and hypertension in adult rat offspring Hypertension 2018 72 962 70 10.1161/HYPERTENSIONAHA.118.10908 30354705
Luo H, Chen C, Guo L, Xu Z, Peng X, Wang X, et al. Exposure to maternal diabetes mellitus causes renal dopamine D1 receptor dysfunction and hypertension in adult rat offspring. Hypertension. 2018;72:962–70.30354705 10.1161/HYPERTENSIONAHA.118.10908
50. Zhu W Petrashevskaya N Ren S Zhao A Chakir K Gao E Gi-biased β2AR signaling links GRK2 upregulation to heart failure Circ Res 2012 110 265 74 10.1161/CIRCRESAHA.111.253260 22179058
Zhu W, Petrashevskaya N, Ren S, Zhao A, Chakir K, Gao E, et al. Gi-biased β2AR signaling links GRK2 upregulation to heart failure. Circ Res. 2012;110:265–74.22179058 10.1161/CIRCRESAHA.111.253260
51. Guo S Carter RL Grisanti LA Koch WJ Tilley DG Impact of paroxetine on proximal β-adrenergic receptor signaling Cell Signal 2017 38 127 33 10.1016/j.cellsig.2017.07.006 28711716
Guo S, Carter RL, Grisanti LA, Koch WJ, Tilley DG. Impact of paroxetine on proximal β-adrenergic receptor signaling. Cell Signal. 2017;38:127–33.28711716 10.1016/j.cellsig.2017.07.006
52. Wang Y Gao E Lau WB Wang Y Liu G Li JJ G-protein-coupled receptor kinase 2-mediated desensitization of adiponectin receptor 1 in failing heart Circulation 2015 131 1392 404 10.1161/CIRCULATIONAHA.114.015248 25696921
Wang Y, Gao E, Lau WB, Wang Y, Liu G, Li JJ, et al. G-protein-coupled receptor kinase 2-mediated desensitization of adiponectin receptor 1 in failing heart. Circulation. 2015;131:1392–404. Apr 2125696921 10.1161/CIRCULATIONAHA.114.015248
53. Chen X Zhao S Xia Y Xiong Z Li Y Tao L G protein coupled receptor kinase-2 upregulation causes κ-opioid receptor desensitization in diabetic heart Biochem Biophys Res Commun 2017 482 658 64 10.1016/j.bbrc.2016.11.090 27865836
Chen X, Zhao S, Xia Y, Xiong Z, Li Y, Tao L, et al. G protein coupled receptor kinase-2 upregulation causes κ-opioid receptor desensitization in diabetic heart. Biochem Biophys Res Commun. 2017;482:658–64.27865836 10.1016/j.bbrc.2016.11.090
54. Pfleger J Gross P Johnson J Carter RL Gao E Tilley DG G protein-coupled receptor kinase 2 contributes to impaired fatty acid metabolism in the failing heart J Mol Cell Cardiol 2018 123 108 17 10.1016/j.yjmcc.2018.08.025 30171848
Pfleger J, Gross P, Johnson J, Carter RL, Gao E, Tilley DG, et al. G protein-coupled receptor kinase 2 contributes to impaired fatty acid metabolism in the failing heart. J Mol Cell Cardiol. 2018;123:108–17.30171848 10.1016/j.yjmcc.2018.08.025
55. Liu J Li X Ding L Li W Niu X Gao D GRK2 participation in cardiac hypertrophy induced by isoproterenol through the regulation of Nrf2 signaling and the promotion of NLRP3 inflammasome and oxidative stress Int Immunopharmacol 2023 117 109957 10.1016/j.intimp.2023.109957 37012864
Liu J, Li X, Ding L, Li W, Niu X, Gao D. GRK2 participation in cardiac hypertrophy induced by isoproterenol through the regulation of Nrf2 signaling and the promotion of NLRP3 inflammasome and oxidative stress. Int Immunopharmacol. 2023;117:109957.37012864 10.1016/j.intimp.2023.109957
56. Bledzka KM Manaserh IH Grondolsky J Pfleger J Roy R Gao E A peptide of the amino-terminus of GRK2 induces hypertrophy and yet elicits cardioprotection after pressure overload J Mol Cell Cardiol 2021 154 137 53 10.1016/j.yjmcc.2021.01.004 33548241
Bledzka KM, Manaserh IH, Grondolsky J, Pfleger J, Roy R, Gao E, et al. A peptide of the amino-terminus of GRK2 induces hypertrophy and yet elicits cardioprotection after pressure overload. J Mol Cell Cardiol. 2021;154:137–53.33548241 10.1016/j.yjmcc.2021.01.004
57. Alonazi ASA Willets JM G protein-coupled receptor kinase 2 is essential to enable vasoconstrictor-mediated arterial smooth muscle proliferation Cell Signal 2021 88 110152 10.1016/j.cellsig.2021.110152 34555505
Alonazi ASA, Willets JM. G protein-coupled receptor kinase 2 is essential to enable vasoconstrictor-mediated arterial smooth muscle proliferation. Cell Signal. 2021;88:110152.34555505 10.1016/j.cellsig.2021.110152
58. Xing W Li Y Zhang H Mi C Hou Z Quon MJ Improvement of vascular insulin sensitivity by downregulation of GRK2 mediates exercise-induced alleviation of hypertension in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol 2013 305 H1111 H1119 10.1152/ajpheart.00290.2013 23913704
Xing W, Li Y, Zhang H, Mi C, Hou Z, Quon MJ, et al. Improvement of vascular insulin sensitivity by downregulation of GRK2 mediates exercise-induced alleviation of hypertension in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2013;305:H1111–H1119.23913704 10.1152/ajpheart.00290.2013
59. Ciccarelli M Sorriento D Franco A Fusco A Del Giudice C Annunziata R Endothelial G protein-coupled receptor kinase 2 regulates vascular homeostasis through the control of free radical oxygen species Arterioscler Thromb Vasc Biol 2013 33 2415 24 10.1161/ATVBAHA.113.302262 23950144
Ciccarelli M, Sorriento D, Franco A, Fusco A, Del Giudice C, Annunziata R, et al. Endothelial G protein-coupled receptor kinase 2 regulates vascular homeostasis through the control of free radical oxygen species. Arterioscler Thromb Vasc Biol. 2013;33:2415–24.23950144 10.1161/ATVBAHA.113.302262
60. Yano H Onoue K Tokinaga S Ioka T Ishihara S Hashimoto Y Overexpression of GRK2 in vascular smooth muscle leads to inappropriate hypertension and acute heart failure as in clinical scenario 1 Sci Rep 2023 13 7707 10.1038/s41598-023-34209-5 37173348
Yano H, Onoue K, Tokinaga S, Ioka T, Ishihara S, Hashimoto Y, et al. Overexpression of GRK2 in vascular smooth muscle leads to inappropriate hypertension and acute heart failure as in clinical scenario 1. Sci Rep. 2023;13:7707.37173348 10.1038/s41598-023-34209-5
61. Zhao Y Vanhoutte PM Leung SW α1-Adrenoceptor activation of PKC-ε causes heterologous desensitization of thromboxane receptors in the aorta of spontaneously hypertensive rats Br J Pharm 2015 172 3687 701 10.1111/bph.13157
Zhao Y, Vanhoutte PM, Leung SW. α1-Adrenoceptor activation of PKC-ε causes heterologous desensitization of thromboxane receptors in the aorta of spontaneously hypertensive rats. Br J Pharm. 2015;172:3687–701.10.1111/bph.13157
62. Montó F Oliver E Vicente D Buendía F Rueda J Agüero J β2- and β1-adrenoceptor expression exhibits a common regulatory pattern with GRK2 and GRK5 in human and animal models of cardiovascular diseases J Cardiovasc Pharm 2015 66 478 86 10.1097/FJC.0000000000000299
Montó F, Oliver E, Vicente D, Buendía F, Rueda J, Agüero J, et al. β2- and β1-adrenoceptor expression exhibits a common regulatory pattern with GRK2 and GRK5 in human and animal models of cardiovascular diseases. J Cardiovasc Pharm. 2015;66:478–86.10.1097/FJC.0000000000000299
63. Gros R Chorazyczewski J Meek MD Benovic JL Ferguson SS Feldman RD G-Protein-coupled receptor kinase activity in hypertension : increased vascular and lymphocyte G-protein receptor kinase-2 protein expression Hypertension 2000 35 38 42 10.1161/01.HYP.35.1.38 10642272
Gros R, Chorazyczewski J, Meek MD, Benovic JL, Ferguson SS, Feldman RD. G-Protein-coupled receptor kinase activity in hypertension : increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension. 2000;35:38–42.10642272 10.1161/01.HYP.35.1.38
64. Oliver E Flacco N Arce C Ivorra MD D’Ocon MP Noguera MA Changes in adrenoceptors and G-protein-coupled receptor kinase 2 in L-NAME-induced hypertension compared to spontaneous hypertension in rats J Vasc Res 2014 51 209 20 10.1159/000360400 24942010
Oliver E, Flacco N, Arce C, Ivorra MD, D’Ocon MP, Noguera MA. Changes in adrenoceptors and G-protein-coupled receptor kinase 2 in L-NAME-induced hypertension compared to spontaneous hypertension in rats. J Vasc Res. 2014;51:209–20.24942010 10.1159/000360400
65. Gros R Tan CM Chorazyczewski J Kelvin DJ Benovic JL Feldman RD G-protein-coupled receptor kinase expression in hypertension Clin Pharm Ther 1999 65 545 51 10.1016/S0009-9236(99)70074-3
Gros R, Tan CM, Chorazyczewski J, Kelvin DJ, Benovic JL, Feldman RD. G-protein-coupled receptor kinase expression in hypertension. Clin Pharm Ther. 1999;65:545–51.10.1016/S0009-9236(99)70074-3
66. Izzo R Cipolletta E Ciccarelli M Campanile A Santulli G Palumbo G Enhanced GRK2 expression and desensitization of beta AR vasodilatation in hypertensive patients Clin Transl Sci 2008 1 215 20 10.1111/j.1752-8062.2008.00050.x 20443852
Izzo R, Cipolletta E, Ciccarelli M, Campanile A, Santulli G, Palumbo G, et al. Enhanced GRK2 expression and desensitization of beta AR vasodilatation in hypertensive patients. Clin Transl Sci. 2008;1:215–20.20443852 10.1111/j.1752-8062.2008.00050.x
67. Cohn HI Xi Y Pesant S Harris DM Hyslop T Falkner B G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in Black Americans Hypertension 2009 54 71 76 10.1161/HYPERTENSIONAHA.108.125955 19487588
Cohn HI, Xi Y, Pesant S, Harris DM, Hyslop T, Falkner B, et al. G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in Black Americans. Hypertension. 2009;54:71–76.19487588 10.1161/HYPERTENSIONAHA.108.125955
68. Li Y Li N Yao X Heizati M Zhang D Zhu Q Association between polymorphisms of ADRBK1 gene and plasma renin activity in hypertensive patients: a case-control study Med Sci Monit 2016 22 2981 8 10.12659/MSM.896579 27555048
Li Y, Li N, Yao X, Heizati M, Zhang D, Zhu Q, et al. Association between polymorphisms of ADRBK1 gene and plasma renin activity in hypertensive patients: a case-control study. Med Sci Monit. 2016;22:2981–8.27555048 10.12659/MSM.896579
69. Napolitano R Campanile A Sarno L Anastasio A Maruotti GM Morlando M GRK2 levels in umbilical arteries of pregnancies complicated by gestational hypertension and preeclampsia Am J Hypertens 2012 25 366 71 10.1038/ajh.2011.211 22089113
Napolitano R, Campanile A, Sarno L, Anastasio A, Maruotti GM, Morlando M, et al. GRK2 levels in umbilical arteries of pregnancies complicated by gestational hypertension and preeclampsia. Am J Hypertens. 2012;25:366–71.22089113 10.1038/ajh.2011.211
70. Lv Z Xiong LL Qin X Zhang H Luo X Peng W Role of GRK2 in trophoblast necroptosis and spiral artery remodeling: implications for preeclampsia pathogenesis Front Cell Dev Biol 2021 9 694261 10.3389/fcell.2021.694261 34917606
Lv Z, Xiong LL, Qin X, Zhang H, Luo X, Peng W, et al. Role of GRK2 in trophoblast necroptosis and spiral artery remodeling: implications for preeclampsia pathogenesis. Front Cell Dev Biol. 2021;9:694261.34917606 10.3389/fcell.2021.694261
71. Yi XP Zhou J Baker J Wang X Gerdes AM Li F Myocardial expression and redistribution of GRKs in hypertensive hypertrophy and failure Anat Rec A Discov Mol Cell Evol Biol 2005 282 13 23 10.1002/ar.a.20143 15584034
Yi XP, Zhou J, Baker J, Wang X, Gerdes AM, Li F. Myocardial expression and redistribution of GRKs in hypertensive hypertrophy and failure. Anat Rec A Discov Mol Cell Evol Biol. 2005;282:13–23.15584034 10.1002/ar.a.20143
72. Oliver E Rovira E Montó F Valldecabres C Julve R Muedra V beta-Adrenoceptor and GRK3 expression in human lymphocytes is related to blood pressure and urinary albumin excretion J Hypertens 2010 28 1281 9 10.1097/HJH.0b013e3283383564 20216086
Oliver E, Rovira E, Montó F, Valldecabres C, Julve R, Muedra V, et al. beta-Adrenoceptor and GRK3 expression in human lymphocytes is related to blood pressure and urinary albumin excretion. J Hypertens. 2010;28:1281–9.20216086 10.1097/HJH.0b013e3283383564
73. Vinge LE von Lueder TG Aasum E Qvigstad E Gravning JA How OJ Cardiac-restricted expression of the carboxyl-terminal fragment of GRK3 uncovers distinct functions of GRK3 in regulation of cardiac contractility and growth: GRK3 controls cardiac alpha1-adrenergic receptor responsiveness J Biol Chem 2008 283 10601 10 10.1074/jbc.M708912200 18165681
Vinge LE, von Lueder TG, Aasum E, Qvigstad E, Gravning JA, How OJ, et al. Cardiac-restricted expression of the carboxyl-terminal fragment of GRK3 uncovers distinct functions of GRK3 in regulation of cardiac contractility and growth: GRK3 controls cardiac alpha1-adrenergic receptor responsiveness. J Biol Chem. 2008;283:10601–10.18165681 10.1074/jbc.M708912200
74. von Lueder TG Gravning J How OJ Vinge LE Ahmed MS Krobert KA Cardiomyocyte-restricted inhibition of G protein-coupled receptor kinase-3 attenuates cardiac dysfunction after chronic pressure overload Am J Physiol Heart Circ Physiol 2012 303 H66 H74 10.1152/ajpheart.00724.2011 22542621
von Lueder TG, Gravning J, How OJ, Vinge LE, Ahmed MS, Krobert KA, et al. Cardiomyocyte-restricted inhibition of G protein-coupled receptor kinase-3 attenuates cardiac dysfunction after chronic pressure overload. Am J Physiol Heart Circ Physiol. 2012;303:H66–H74.22542621 10.1152/ajpheart.00724.2011
75. Sedaghat K Tiberi M Cytoplasmic tail of D1 dopaminergic receptor differentially regulates desensitization and phosphorylation by G protein-coupled receptor kinase 2 and 3 Cell Signal 2011 23 180 92 10.1016/j.cellsig.2010.09.002 20837135
Sedaghat K, Tiberi M. Cytoplasmic tail of D1 dopaminergic receptor differentially regulates desensitization and phosphorylation by G protein-coupled receptor kinase 2 and 3. Cell Signal. 2011;23:180–92.20837135 10.1016/j.cellsig.2010.09.002
76. Maimari T Krasel C Bünemann M Lorenz K The N-termini of GRK2 and GRK3 simulate the stimulating effects of RKIP on β-adrenoceptors Biochem Biophys Res Commun 2019 520 327 32 10.1016/j.bbrc.2019.09.135 31604529
Maimari T, Krasel C, Bünemann M, Lorenz K. The N-termini of GRK2 and GRK3 simulate the stimulating effects of RKIP on β-adrenoceptors. Biochem Biophys Res Commun. 2019;520:327–32.31604529 10.1016/j.bbrc.2019.09.135
77. Chen K Fu C Chen C Liu L Ren H Han Y Role of GRK4 in the regulation of arterial AT1 receptor in hypertension Hypertension 2014 63 289 96 10.1161/HYPERTENSIONAHA.113.01766 24218433
Chen K, Fu C, Chen C, Liu L, Ren H, Han Y, et al. Role of GRK4 in the regulation of arterial AT1 receptor in hypertension. Hypertension. 2014;63:289–96.24218433 10.1161/HYPERTENSIONAHA.113.01766
78. Wang Z Zeng C Villar VA Chen SY Konkalmatt P Wang X Human GRK4γ142V variant promotes AT1R-mediated hypertension via renal HDAC1 inhibition Hypertension. 2016 67 325 34 10.1161/HYPERTENSIONAHA.115.05962 26667412
Wang Z, Zeng C, Villar VA, Chen SY, Konkalmatt P, Wang X, et al. Human GRK4γ142V variant promotes AT1R-mediated hypertension via renal HDAC1 inhibition. Hypertension. 2016;67:325–34.26667412 10.1161/HYPERTENSIONAHA.115.05962
79. Sanada H Yatabe J Midorikawa S Katoh T Hashimoto S Watanabe T Amelioration of genetic hypertension by suppression of renal G protein-coupled receptor kinase type 4 expression Hypertension 2006 47 1131 9 10.1161/01.HYP.0000222004.74872.17 16636192
Sanada H, Yatabe J, Midorikawa S, Katoh T, Hashimoto S, Watanabe T, et al. Amelioration of genetic hypertension by suppression of renal G protein-coupled receptor kinase type 4 expression. Hypertension. 2006;47:1131–9.16636192 10.1161/01.HYP.0000222004.74872.17
80. Yatabe J Sanada H Midorikawa S Hashimoto S Watanabe T Andrews PM Effects of decreased renal cortical expression of G protein-coupled receptor kinase 4 and angiotensin type 1 receptors in rats Hypertens Res 2008 31 1455 64 10.1291/hypres.31.1455 18957817
Yatabe J, Sanada H, Midorikawa S, Hashimoto S, Watanabe T, Andrews PM, et al. Effects of decreased renal cortical expression of G protein-coupled receptor kinase 4 and angiotensin type 1 receptors in rats. Hypertens Res. 2008;31:1455–64.18957817 10.1291/hypres.31.1455
81. Huang H Li X Zheng S Chen Y Chen C Wang J Downregulation of renal G protein-coupled receptor kinase type 4 expression via ultrasound-targeted microbubble destruction lowers blood pressure in spontaneously hypertensive rats J Am Heart Assoc 2016 5 e004028 10.1161/JAHA.116.004028 27792639
Huang H, Li X, Zheng S, Chen Y, Chen C, Wang J, et al. Downregulation of renal G protein-coupled receptor kinase type 4 expression via ultrasound-targeted microbubble destruction lowers blood pressure in spontaneously hypertensive rats. J Am Heart Assoc. 2016;5:e004028.27792639 10.1161/JAHA.116.004028
82. Yang Y Li M Zou X Chen C Zheng S Fu C Role of GRK4 in the regulation of the renal ETB receptor in hypertension FASEB J 2020 34 11594 604 10.1096/fj.201902552R 32687659
Yang Y, Li M, Zou X, Chen C, Zheng S, Fu C, et al. Role of GRK4 in the regulation of the renal ETB receptor in hypertension. FASEB J. 2020;34:11594–604.32687659 10.1096/fj.201902552R
83. Diao Z Asico LD Villar VAM Zheng X Cuevas S Armando I Increased renal oxidative stress in salt-sensitive human GRK4γ486V transgenic mice Free Radic Biol Med 2017 106 80 90 10.1016/j.freeradbiomed.2017.02.021 28189851
Diao Z, Asico LD, Villar VAM, Zheng X, Cuevas S, Armando I, et al. Increased renal oxidative stress in salt-sensitive human GRK4γ486V transgenic mice. Free Radic Biol Med. 2017;106:80–90.28189851 10.1016/j.freeradbiomed.2017.02.021
84. Allen SJ Parthasarathy G Darke PL Diehl RE Ford RE Hall DL Structure and function of the hypertension variant A486V of G protein-coupled receptor kinase 4 J Biol Chem 2015 290 20360 73 10.1074/jbc.M115.648907 26134571
Allen SJ, Parthasarathy G, Darke PL, Diehl RE, Ford RE, Hall DL, et al. Structure and function of the hypertension variant A486V of G protein-coupled receptor kinase 4. J Biol Chem. 2015;290:20360–73.26134571 10.1074/jbc.M115.648907
85. Rankin ML Marinec PS Cabrera DM Wang Z Jose PA Sibley DR The D1 dopamine receptor is constitutively phosphorylated by G protein-coupled receptor kinase 4 Mol Pharm 2006 69 759 69 10.1124/mol.105.019901
Rankin ML, Marinec PS, Cabrera DM, Wang Z, Jose PA, Sibley DR. The D1 dopamine receptor is constitutively phosphorylated by G protein-coupled receptor kinase 4. Mol Pharm. 2006;69:759–69.10.1124/mol.105.019901
86. Watanabe H Xu J Bengra C Jose PA Felder RA Desensitization of human renal D1 dopamine receptors by G protein-coupled receptor kinase 4 Kidney Int 2002 62 790 8 10.1046/j.1523-1755.2002.00525.x 12164861
Watanabe H, Xu J, Bengra C, Jose PA, Felder RA. Desensitization of human renal D1 dopamine receptors by G protein-coupled receptor kinase 4. Kidney Int. 2002;62:790–8.12164861 10.1046/j.1523-1755.2002.00525.x
87. Ye Z Lu X Deng Y Wang X Zheng S Ren H In Utero exposure to fine particulate matter causes hypertension due to impaired renal dopamine D1 receptor in offspring Cell Physiol Biochem 2018 46 148 59 10.1159/000488418 29614490
Ye Z, Lu X, Deng Y, Wang X, Zheng S, Ren H, et al. In Utero exposure to fine particulate matter causes hypertension due to impaired renal dopamine D1 receptor in offspring. Cell Physiol Biochem. 2018;46:148–59.29614490 10.1159/000488418
88. Wang X Luo H Chen C Chen K Wang J Cai Y Prenatal lipopolysaccharide exposure results in dysfunction of the renal dopamine D1 receptor in offspring Free Radic Biol Med 2014 76 242 50 10.1016/j.freeradbiomed.2014.08.010 25236748
Wang X, Luo H, Chen C, Chen K, Wang J, Cai Y, et al. Prenatal lipopolysaccharide exposure results in dysfunction of the renal dopamine D1 receptor in offspring. Free Radic Biol Med. 2014;76:242–50.25236748 10.1016/j.freeradbiomed.2014.08.010
89. Sun D Chen K Wang J Zhou L Zeng C In-utero cold stress causes elevation of blood pressure via impaired vascular dopamine D1 receptor in offspring Clin Exp Hypertens 2020 42 99 104 10.1080/10641963.2019.1571603 30698033
Sun D, Chen K, Wang J, Zhou L, Zeng C. In-utero cold stress causes elevation of blood pressure via impaired vascular dopamine D1 receptor in offspring. Clin Exp Hypertens. 2020;42:99–104.30698033 10.1080/10641963.2019.1571603
90. Tao Y Luo W Chen Y Chen C Chen S Li X Exercise ameliorates skeletal muscle insulin resistance by modulating GRK4-mediated D1R expression Clin Sci 2023 137 1391 407 10.1042/CS20230664
Tao Y, Luo W, Chen Y, Chen C, Chen S, Li X, et al. Exercise ameliorates skeletal muscle insulin resistance by modulating GRK4-mediated D1R expression. Clin Sci. 2023;137:1391–407.10.1042/CS20230664
91. Villar VA Jones JE Armando I Palmes-Saloma C Yu P Pascua AM G protein-coupled receptor kinase 4 (GRK4) regulates the phosphorylation and function of the dopamine D3 receptor J Biol Chem 2009 284 21425 34 10.1074/jbc.M109.003665 19520868
Villar VA, Jones JE, Armando I, Palmes-Saloma C, Yu P, Pascua AM, et al. G protein-coupled receptor kinase 4 (GRK4) regulates the phosphorylation and function of the dopamine D3 receptor. J Biol Chem. 2009;284:21425–34.19520868 10.1074/jbc.M109.003665
92. Hu C Tao Y Deng Y Cai Q Ren H Yu C Paternal long-term PM2.5 exposure causes hypertension via increased renal AT1R expression and function in male offspring Clin Sci (Lond) 2021 135 2575 88 10.1042/CS20210802 34779863
Hu C, Tao Y, Deng Y, Cai Q, Ren H, Yu C, et al. Paternal long-term PM2.5 exposure causes hypertension via increased renal AT1R expression and function in male offspring. Clin Sci (Lond). 2021;135:2575–88.34779863 10.1042/CS20210802
93. Zhang F Lei L Huang J Wang W Su Q Yan H G-protein-coupled receptor kinase 4 causes renal angiotensin II type 2 receptor dysfunction by increasing its phosphorylation Clin Sci 2022 136 989 1003 10.1042/CS20220236
Zhang F, Lei L, Huang J, Wang W, Su Q, Yan H, et al. G-protein-coupled receptor kinase 4 causes renal angiotensin II type 2 receptor dysfunction by increasing its phosphorylation. Clin Sci. 2022;136:989–1003.10.1042/CS20220236
94. Lu X Ye Z Zheng S Ren H Zeng J Wang X Long-term exposure of fine particulate matter causes hypertension by impaired renal D1 receptor-mediated sodium excretion via upregulation of G-protein-coupled receptor kinase type 4 expression in Sprague-Dawley rats J Am Heart Assoc 2018 7 e007185 10.1161/JAHA.117.007185 29307864
Lu X, Ye Z, Zheng S, Ren H, Zeng J, Wang X, et al. Long-term exposure of fine particulate matter causes hypertension by impaired renal D1 receptor-mediated sodium excretion via upregulation of G-protein-coupled receptor kinase type 4 expression in Sprague-Dawley rats. J Am Heart Assoc. 2018;7:e007185.29307864 10.1161/JAHA.117.007185
95. Chugh G Lokhandwala MF Asghar M Altered functioning of both renal dopamine D1 and angiotensin II type 1 receptors causes hypertension in old rats Hypertension 2012 59 1029 36 10.1161/HYPERTENSIONAHA.112.192302 22411927
Chugh G, Lokhandwala MF, Asghar M. Altered functioning of both renal dopamine D1 and angiotensin II type 1 receptors causes hypertension in old rats. Hypertension. 2012;59:1029–36.22411927 10.1161/HYPERTENSIONAHA.112.192302
96. Escano CS Armando I Wang X Asico LD Pascua A Yang Y Renal dopaminergic defect in C57Bl/6J mice Am J Physiol Regul Integr Comp Physiol 2009 297 R1660 R1669 10.1152/ajpregu.00147.2009 19726707
Escano CS, Armando I, Wang X, Asico LD, Pascua A, Yang Y, et al. Renal dopaminergic defect in C57Bl/6J mice. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1660–R1669.19726707 10.1152/ajpregu.00147.2009
97. Jones ES Spence JD Mcintyre AD Nondi J Gogo K Akintunde A High frequency of variants of candidate genes in Black Africans with low renin-resistant hypertension Am J Hypertens 2017 30 478 83 10.1093/ajh/hpw167 28052878
Jones ES, Spence JD, Mcintyre AD, Nondi J, Gogo K, Akintunde A, et al. High frequency of variants of candidate genes in Black Africans with low renin-resistant hypertension. Am J Hypertens. 2017;30:478–83.28052878 10.1093/ajh/hpw167
98. Kimura L Angeli CB Auricchio MT Fernandes GR Pereira AC Vicente JP Multilocus family-based association analysis of seven candidate polymorphisms with essential hypertension in an African-derived semi-isolated Brazilian population Int J Hypertens 2012 2012 859219 10.1155/2012/859219 23056922
Kimura L, Angeli CB, Auricchio MT, Fernandes GR, Pereira AC, Vicente JP, et al. Multilocus family-based association analysis of seven candidate polymorphisms with essential hypertension in an African-derived semi-isolated Brazilian population. Int J Hypertens. 2012;2012:859219.23056922 10.1155/2012/859219
99. Sanada H Yatabe J Midorikawa S Hashimoto S Watanabe T Moore JH Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension Clin Chem 2006 52 352 60 10.1373/clinchem.2005.059139 16439609
Sanada H, Yatabe J, Midorikawa S, Hashimoto S, Watanabe T, Moore JH, et al. Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension. Clin Chem. 2006;52:352–60.16439609 10.1373/clinchem.2005.059139
100. Gu D Su S Ge D Chen S Huang J Li B Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese Hypertension 2006 47 1147 54 10.1161/01.HYP.0000219041.66702.45 16636198
Gu D, Su S, Ge D, Chen S, Huang J, Li B, et al. Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese. Hypertension. 2006;47:1147–54.16636198 10.1161/01.HYP.0000219041.66702.45
101. Speirs HJ Katyk K Kumar NN Benjafield AV Wang WY Morris BJ Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension J Hypertens 2004 22 931 6 10.1097/00004872-200405000-00014 15097232
Speirs HJ, Katyk K, Kumar NN, Benjafield AV, Wang WY, Morris BJ. Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension. J Hypertens. 2004;22:931–6.15097232 10.1097/00004872-200405000-00014
102. Bengra C Mifflin TE Khripin Y Manunta P Williams SM Jose PA Genotyping of essential hypertension single-nucleotide polymorphisms by a homogeneous PCR method with universal energy transfer primers Clin Chem 2002 48 2131 40 10.1093/clinchem/48.12.2131 12446468
Bengra C, Mifflin TE, Khripin Y, Manunta P, Williams SM, Jose PA, et al. Genotyping of essential hypertension single-nucleotide polymorphisms by a homogeneous PCR method with universal energy transfer primers. Clin Chem. 2002;48:2131–40.12446468 10.1093/clinchem/48.12.2131
103. Jeong S Kim JY Cho Y Koh SB Kim N Choi JR Genetically, dietary sodium intake is causally associated with salt-sensitive hypertension risk in a community-based cohort study: a mendelian randomization approach Curr Hypertens Rep 2020 22 45 10.1007/s11906-020-01050-4 32591971
Jeong S, Kim JY, Cho Y, Koh SB, Kim N, Choi JR. Genetically, dietary sodium intake is causally associated with salt-sensitive hypertension risk in a community-based cohort study: a mendelian randomization approach. Curr Hypertens Rep. 2020;22:45.32591971 10.1007/s11906-020-01050-4
104. Jiang W Wang X Li R Wang P Shan G Jia X Targeted capture sequencing identifies genetic variations of GRK4 and RDH8 in Han Chinese with essential hypertension in Xinjiang PLoS One 2021 16 e0255311 10.1371/journal.pone.0255311 34297769
Jiang W, Wang X, Li R, Wang P, Shan G, Jia X, et al. Targeted capture sequencing identifies genetic variations of GRK4 and RDH8 in Han Chinese with essential hypertension in Xinjiang. PLoS One. 2021;16:e0255311.34297769 10.1371/journal.pone.0255311
105. Du B Jia X Tian W Yan X Wang N Cai D Associations of SUCNR1, GRK4, CAMK1D gene polymorphisms and the susceptibility of type 2 diabetes mellitus and essential hypertension in a northern Chinese Han population J Diabetes Complic 2021 35 107752 10.1016/j.jdiacomp.2020.107752
Du B, Jia X, Tian W, Yan X, Wang N, Cai D, et al. Associations of SUCNR1, GRK4, CAMK1D gene polymorphisms and the susceptibility of type 2 diabetes mellitus and essential hypertension in a northern Chinese Han population. J Diabetes Complic. 2021;35:107752.10.1016/j.jdiacomp.2020.107752
106. Zhang H Sun ZQ Liu SS Yang LN Association between GRK4 and DRD1 gene polymorphisms and hypertension: a meta-analysis Clin Int Aging 2015 11 17 27 10.2147/CIA.S94510
Zhang H, Sun ZQ, Liu SS, Yang LN. Association between GRK4 and DRD1 gene polymorphisms and hypertension: a meta-analysis. Clin Int Aging. 2015;11:17–27.10.2147/CIA.S94510
107. Carey RM Schoeffel CD Gildea JJ Jones JE McGrath HE Gordon LN Salt sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbonate cotransporter Hypertension 2012 60 1359 66 10.1161/HYPERTENSIONAHA.112.196071 22987918
Carey RM, Schoeffel CD, Gildea JJ, Jones JE, McGrath HE, Gordon LN, et al. Salt sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbonate cotransporter. Hypertension. 2012;60:1359–66.22987918 10.1161/HYPERTENSIONAHA.112.196071
108. Williams SM Ritchie MD Phillips JA 3rd Dawson E Prince M Dzhura E Multilocus analysis of hypertension: a hierarchical approach Hum Hered 2004 57 28 38 10.1159/000077387 15133310
Williams SM, Ritchie MD, Phillips JA 3rd, Dawson E, Prince M, Dzhura E, et al. Multilocus analysis of hypertension: a hierarchical approach. Hum Hered. 2004;57:28–38.15133310 10.1159/000077387
109. Liu C Xi B Pooled analyses of the associations of polymorphisms in the GRK4 and EMILIN1 genes with hypertension risk Int J Med Sci 2012 9 274 9 10.7150/ijms.4171 22639547
Liu C, Xi B. Pooled analyses of the associations of polymorphisms in the GRK4 and EMILIN1 genes with hypertension risk. Int J Med Sci. 2012;9:274–9.22639547 10.7150/ijms.4171
110. Zilbermint M Hannah-Shmouni F Stratakis CA Genetics of hypertension in African Americans and others of African descent Int J Mol Sci 2019 20 1081 10.3390/ijms20051081 30832344
Zilbermint M, Hannah-Shmouni F, Stratakis CA. Genetics of hypertension in African Americans and others of African descent. Int J Mol Sci. 2019;20:1081.30832344 10.3390/ijms20051081
111. Bhatnagar V O’Connor DT Brophy VH Schork NJ Richard E Salem RM G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions Am J Hypertens 2009 22 332 8 10.1038/ajh.2008.341 19119263
Bhatnagar V, O’Connor DT, Brophy VH, Schork NJ, Richard E, Salem RM, et al. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009;22:332–8.19119263 10.1038/ajh.2008.341
112. Martinez Cantarin MP Ertel A Deloach S Fortina P Scott K Burns TL Variants in genes involved in functional pathways associated with hypertension in African Americans Clin Transl Sci 2010 3 279 86 10.1111/j.1752-8062.2010.00242.x 21167003
Martinez Cantarin MP, Ertel A, Deloach S, Fortina P, Scott K, Burns TL, et al. Variants in genes involved in functional pathways associated with hypertension in African Americans. Clin Transl Sci. 2010;3:279–86.21167003 10.1111/j.1752-8062.2010.00242.x
113. Lohmueller KE Wong LJ Mauney MM Jiang L Felder RA Jose PA Patterns of genetic variation in the hypertension candidate gene GRK4: ethnic variation and haplotype structure Ann Hum Genet 2006 70 27 41 10.1111/j.1529-8817.2005.00197.x 16441255
Lohmueller KE, Wong LJ, Mauney MM, Jiang L, Felder RA, Jose PA, et al. Patterns of genetic variation in the hypertension candidate gene GRK4: ethnic variation and haplotype structure. Ann Hum Genet. 2006;70:27–41.16441255 10.1111/j.1529-8817.2005.00197.x
114. Staessen JA Kuznetsova T Zhang H Maillard M Bochud M Hasenkamp S Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4 Hypertension 2008 51 1643 50 10.1161/HYPERTENSIONAHA.107.109611 18413491
Staessen JA, Kuznetsova T, Zhang H, Maillard M, Bochud M, Hasenkamp S, et al. Blood pressure and renal sodium handling in relation to genetic variation in the DRD1 promoter and GRK4. Hypertension. 2008;51:1643–50.18413491 10.1161/HYPERTENSIONAHA.107.109611
115. Cheng CF Lin YJ Lin MC Liang WM Chen CC Chen CH Genetic risk score constructed from common genetic variants is associated with cardiovascular disease risk in type 2 diabetes mellitus J Gene Med 2021 23 e3305 10.1002/jgm.3305 33350037
Cheng CF, Lin YJ, Lin MC, Liang WM, Chen CC, Chen CH, et al. Genetic risk score constructed from common genetic variants is associated with cardiovascular disease risk in type 2 diabetes mellitus. J Gene Med. 2021;23:e3305.33350037 10.1002/jgm.3305
116. Lee M Kim MK Kim SM Park H Park CG Park HK Gender-based differences on the association between salt-sensitive genes and obesity in Korean children aged between 8 and 9 years PLoS One 2015 10 e0120111 10.1371/journal.pone.0120111 25768006
Lee M, Kim MK, Kim SM, Park H, Park CG, Park HK. Gender-based differences on the association between salt-sensitive genes and obesity in Korean children aged between 8 and 9 years. PLoS One. 2015;10:e0120111.25768006 10.1371/journal.pone.0120111
117. Zhu H Lu Y Wang X Snieder H Treiber FA Harshfield GA The G protein-coupled receptor kinase 4 gene modulates stress-induced sodium excretion in Black normotensive adolescents Pediatr Res 2006 60 440 2 10.1203/01.pdr.0000238250.64591.44 16940246
Zhu H, Lu Y, Wang X, Snieder H, Treiber FA, Harshfield GA, et al. The G protein-coupled receptor kinase 4 gene modulates stress-induced sodium excretion in Black normotensive adolescents. Pediatr Res. 2006;60:440–2.16940246 10.1203/01.pdr.0000238250.64591.44
118. Marzano F Liccardo D Elia A Mucio I de Lucia C Lucchese AM Genetic catalytic inactivation of GRK5 impairs cardiac function in mice via dysregulated P53 levels JACC Basic Transl Sci 2022 7 366 80 10.1016/j.jacbts.2022.01.001 35540100
Marzano F, Liccardo D, Elia A, Mucio I, de Lucia C, Lucchese AM, et al. Genetic catalytic inactivation of GRK5 impairs cardiac function in mice via dysregulated P53 levels. JACC Basic Transl Sci. 2022;7:366–80.35540100 10.1016/j.jacbts.2022.01.001
119. de Lucia C Grisanti LA Borghetti G Piedepalumbo M Ibetti J Lucchese AM G protein-coupled receptor kinase 5 (GRK5) contributes to impaired cardiac function and immune cell recruitment in post-ischemic heart failure Cardiovasc Res 2022 118 169 83 10.1093/cvr/cvab044 33560342
de Lucia C, Grisanti LA, Borghetti G, Piedepalumbo M, Ibetti J, Lucchese AM, et al. G protein-coupled receptor kinase 5 (GRK5) contributes to impaired cardiac function and immune cell recruitment in post-ischemic heart failure. Cardiovasc Res. 2022;118:169–83.33560342 10.1093/cvr/cvab044
120. Xu B Li M Wang Y Zhao M Morotti S Shi Q GRK5 controls SAP97-dependent cardiotoxic β1 adrenergic receptor-CaMKII signaling in heart failure Circ Res 2020 127 796 810 10.1161/CIRCRESAHA.119.316319 32507058
Xu B, Li M, Wang Y, Zhao M, Morotti S, Shi Q, et al. GRK5 controls SAP97-dependent cardiotoxic β1 adrenergic receptor-CaMKII signaling in heart failure. Circ Res. 2020;127:796–810.32507058 10.1161/CIRCRESAHA.119.316319
121. Ishizaka N Alexander RW Laursen JB Kai H Fukui T Oppermann M G protein-coupled receptor kinase 5 in cultured vascular smooth muscle cells and rat aorta. Regulation by angiotensin II and hypertension J Biol Chem 1997 272 32482 8 10.1074/jbc.272.51.32482 9405459
Ishizaka N, Alexander RW, Laursen JB, Kai H, Fukui T, Oppermann M, et al. G protein-coupled receptor kinase 5 in cultured vascular smooth muscle cells and rat aorta. Regulation by angiotensin II and hypertension. J Biol Chem. 1997;272:32482–8.9405459 10.1074/jbc.272.51.32482
122. Keys JR Zhou RH Harris DM Druckman CA Eckhart AD Vascular smooth muscle overexpression of G protein-coupled receptor kinase 5 elevates blood pressure, which segregates with sex and is dependent on Gi-mediated signaling Circulation 2005 112 1145 53 10.1161/CIRCULATIONAHA.104.531657 16103237
Keys JR, Zhou RH, Harris DM, Druckman CA, Eckhart AD. Vascular smooth muscle overexpression of G protein-coupled receptor kinase 5 elevates blood pressure, which segregates with sex and is dependent on Gi-mediated signaling. Circulation. 2005;112:1145–53.16103237 10.1161/CIRCULATIONAHA.104.531657
123. Sorriento D Santulli G Fusco A Anastasio A Trimarco B Iaccarino G Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression Hypertension 2010 56 696 704 10.1161/HYPERTENSIONAHA.110.155960 20660817
Sorriento D, Santulli G, Fusco A, Anastasio A, Trimarco B, Iaccarino G. Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression. Hypertension. 2010;56:696–704.20660817 10.1161/HYPERTENSIONAHA.110.155960
124. Wang L Shen M Wang F Ma L GRK5 ablation contributes to insulin resistance Biochem Biophys Res Commun 2012 429 99 104 10.1016/j.bbrc.2012.10.077 23111327
Wang L, Shen M, Wang F, Ma L. GRK5 ablation contributes to insulin resistance. Biochem Biophys Res Commun. 2012;429:99–104.23111327 10.1016/j.bbrc.2012.10.077
125. da Silva AA do Carmo JM Li X Wang Z Mouton AJ Hall JE Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited Can J Cardiol 2020 36 671 82 10.1016/j.cjca.2020.02.066 32389340
da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited. Can J Cardiol. 2020;36:671–82.32389340 10.1016/j.cjca.2020.02.066
126. Lutz SZ Falcenberg M Machicao F Peter A Kächele M Randrianarisoa E Single nucleotide polymorphisms in the G-protein coupled receptor kinase 5 (GRK5) gene are associated with plasma LDL-cholesterol levels in humans Sci Rep 2018 8 7745 10.1038/s41598-018-26055-7 29773828
Lutz SZ, Falcenberg M, Machicao F, Peter A, Kächele M, Randrianarisoa E, et al. Single nucleotide polymorphisms in the G-protein coupled receptor kinase 5 (GRK5) gene are associated with plasma LDL-cholesterol levels in humans. Sci Rep. 2018;8:7745.29773828 10.1038/s41598-018-26055-7
127. Kang S Hong X Ruan CW Yu P Yu SS Chen M Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure J Transl Med 2015 13 44 10.1186/s12967-015-0402-7 25638254
Kang S, Hong X, Ruan CW, Yu P, Yu SS, Chen M, et al. Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure. J Transl Med. 2015;13:44.25638254 10.1186/s12967-015-0402-7
128. Cresci S Kelly RJ Cappola TP Diwan A Dries D Kardia SL Clinical and genetic modifiers of long-term survival in heart failure J Am Coll Cardiol 2009 54 432 44 10.1016/j.jacc.2009.05.009 19628119
Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009;54:432–44.19628119 10.1016/j.jacc.2009.05.009
129. Stegen M Frey UH The role of G protein-coupled receptor kinase 6 regulation in inflammation and pain Int J Mol Sci 2022 23 15880 10.3390/ijms232415880 36555521
Stegen M, Frey UH. The role of G protein-coupled receptor kinase 6 regulation in inflammation and pain. Int J Mol Sci. 2022;23:15880.36555521 10.3390/ijms232415880
130. Fraga S Luo Y Jose P Zandi-Nejad K Mount DB Soares-da-Silva P Dopamine D1-like receptor-mediated inhibition of Cl/HCO3- exchanger activity in rat intestinal epithelial IEC-6 cells is regulated by G protein-coupled receptor kinase 6 (GRK 6) Cell Physiol Biochem 2006 18 347 60 10.1159/000097612 17170521
Fraga S, Luo Y, Jose P, Zandi-Nejad K, Mount DB, Soares-da-Silva P. Dopamine D1-like receptor-mediated inhibition of Cl/HCO3- exchanger activity in rat intestinal epithelial IEC-6 cells is regulated by G protein-coupled receptor kinase 6 (GRK 6). Cell Physiol Biochem. 2006;18:347–60.17170521 10.1159/000097612
131. Fraga S Jose PA Soares-da-Silva P Involvement of G protein-coupled receptor kinase 4 and 6 in rapid desensitization of dopamine D1 receptor in rat IEC-6 intestinal epithelial cells Am J Physiol Regul Integr Comp Physiol 2004 287 R772 R779 10.1152/ajpregu.00208.2004 15166006
Fraga S, Jose PA, Soares-da-Silva P. Involvement of G protein-coupled receptor kinase 4 and 6 in rapid desensitization of dopamine D1 receptor in rat IEC-6 intestinal epithelial cells. Am J Physiol Regul Integr Comp Physiol. 2004;287:R772–R779.15166006 10.1152/ajpregu.00208.2004
132. Rajagopal K Whalen EJ Violin JD Stiber JA Rosenberg PB Premont RT Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes Proc Natl Acad Sci USA 2006 103 16284 9 10.1073/pnas.0607583103 17060617
Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA. 2006;103:16284–9.17060617 10.1073/pnas.0607583103
133. Wang L Bao H Wang KX Zhang P Yao QP Chen XH Secreted miR-27a induced by cyclic stretch modulates the proliferation of endothelial cells in hypertension via GRK6 Sci Rep 2017 7 41058 10.1038/srep41058 28106155
Wang L, Bao H, Wang KX, Zhang P, Yao QP, Chen XH, et al. Secreted miR-27a induced by cyclic stretch modulates the proliferation of endothelial cells in hypertension via GRK6. Sci Rep. 2017;7:41058.28106155 10.1038/srep41058
134. Soliman RH Pollock DM Circadian control of sodium and blood pressure regulation Am J Hypertens 2021 34 1130 42 10.1093/ajh/hpab100 34166494
Soliman RH, Pollock DM. Circadian control of sodium and blood pressure regulation. Am J Hypertens. 2021;34:1130–42.34166494 10.1093/ajh/hpab100
135. Palaniappan B Arthur S Sundaram VL Butts M Sundaram S Mani K Inhibition of intestinal villus cell Na/K-ATPase mediates altered glucose and NaCl absorption in obesity-associated diabetes and hypertension FASEB J 2019 33 9323 33 10.1096/fj.201802673R 31107610
Palaniappan B, Arthur S, Sundaram VL, Butts M, Sundaram S, Mani K, et al. Inhibition of intestinal villus cell Na/K-ATPase mediates altered glucose and NaCl absorption in obesity-associated diabetes and hypertension. FASEB J. 2019;33:9323–33.31107610 10.1096/fj.201802673R
136. Nwia SM Li XC Leite APO Hassan R Zhuo JL The Na+/H+ Exchanger 3 in the intestines and the proximal tubule of the kidney: localization, physiological function, and key roles in angiotensin II-induced hypertension Front Physiol 2022 13 861659 10.3389/fphys.2022.861659 35514347
Nwia SM, Li XC, Leite APO, Hassan R, Zhuo JL. The Na+/H+ Exchanger 3 in the intestines and the proximal tubule of the kidney: localization, physiological function, and key roles in angiotensin II-induced hypertension. Front Physiol. 2022;13:861659.35514347 10.3389/fphys.2022.861659
137. Sakr HF Sirasanagandla SR Das S Bima AI Elsamanoudy AZ Insulin resistance and hypertension: mechanisms involved and modifying factors for effective glucose control Biomedicines 2023 11 2271 10.3390/biomedicines11082271 37626767
Sakr HF, Sirasanagandla SR, Das S, Bima AI, Elsamanoudy AZ. Insulin resistance and hypertension: mechanisms involved and modifying factors for effective glucose control. Biomedicines. 2023;11:2271.37626767 10.3390/biomedicines11082271
138. Varney MJ Steyaert W Coucke PJ Delanghe JR Uehling DE Joseph B G protein-coupled receptor kinase 6 (GRK6) regulates insulin processing and secretion via effects on proinsulin conversion to insulin J Biol Chem 2022 298 102421 10.1016/j.jbc.2022.102421 36030052
Varney MJ, Steyaert W, Coucke PJ, Delanghe JR, Uehling DE, Joseph B, et al. G protein-coupled receptor kinase 6 (GRK6) regulates insulin processing and secretion via effects on proinsulin conversion to insulin. J Biol Chem. 2022;298:102421.36030052 10.1016/j.jbc.2022.102421
139. Guo J Chen H Ho J Mancini J Sontag T Laporte SA TGFbeta-induced GRK2 expression attenuates Ang II-regulated vascular smooth muscle cell proliferation and migration Cell Signal 2009 21 899 905 10.1016/j.cellsig.2009.01.037 19385060
Guo J, Chen H, Ho J, Mancini J, Sontag T, Laporte SA, et al. TGFbeta-induced GRK2 expression attenuates Ang II-regulated vascular smooth muscle cell proliferation and migration. Cell Signal. 2009;21:899–905.19385060 10.1016/j.cellsig.2009.01.037
140. Gildea JJ Tran HT Van Sciver RE Bigler Wang D Carlson JM Felder RA A novel role for c-Myc in G protein-coupled receptor kinase 4 (GRK4) transcriptional regulation in human kidney proximal tubule cells Hypertension 2013 61 1021 7 10.1161/HYPERTENSIONAHA.111.00321 23509080
Gildea JJ, Tran HT, Van Sciver RE, Bigler Wang D, Carlson JM, Felder RA. A novel role for c-Myc in G protein-coupled receptor kinase 4 (GRK4) transcriptional regulation in human kidney proximal tubule cells. Hypertension. 2013;61:1021–7.23509080 10.1161/HYPERTENSIONAHA.111.00321
141. Yang M Lin Y Wang Y Wang Y High-glucose induces cardiac myocytes apoptosis through Foxo1/GRK2 signaling pathway Biochem Biophys Res Commun 2019 513 154 8 10.1016/j.bbrc.2019.03.193 30952428
Yang M, Lin Y, Wang Y, Wang Y. High-glucose induces cardiac myocytes apoptosis through Foxo1/GRK2 signaling pathway. Biochem Biophys Res Commun. 2019;513:154–8.30952428 10.1016/j.bbrc.2019.03.193
142. Islam KN Koch WJ Involvement of nuclear factor κB (NF-κB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression J Biol Chem 2012 287 12771 8 10.1074/jbc.M111.324566 22389501
Islam KN, Koch WJ. Involvement of nuclear factor κB (NF-κB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression. J Biol Chem. 2012;287:12771–8.22389501 10.1074/jbc.M111.324566
143. Stegen M Engler A Ochsenfarth C Manthey I Peters J Siffert W Characterization of the G protein-coupled receptor kinase 6 promoter reveals a functional CREB binding site PLoS One 2021 16 e0247087 10.1371/journal.pone.0247087 33600497
Stegen M, Engler A, Ochsenfarth C, Manthey I, Peters J, Siffert W, et al. Characterization of the G protein-coupled receptor kinase 6 promoter reveals a functional CREB binding site. PLoS One. 2021;16:e0247087.33600497 10.1371/journal.pone.0247087
144. Taguchi K Kobayashi T Matsumoto T Kamata K Dysfunction of endothelium-dependent relaxation to insulin via PKC-mediated GRK2/Akt activation in aortas of ob/ob mice Am J Physiol Heart Circ Physiol 2011 301 H571 H583 10.1152/ajpheart.01189.2010 21572010
Taguchi K, Kobayashi T, Matsumoto T, Kamata K. Dysfunction of endothelium-dependent relaxation to insulin via PKC-mediated GRK2/Akt activation in aortas of ob/ob mice. Am J Physiol Heart Circ Physiol. 2011;301:H571–H583.21572010 10.1152/ajpheart.01189.2010
145. Penela P Ruiz-Gómez A Castaño JG Mayor F Jr Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway J Biol Chem 1998 273 35238 44 10.1074/jbc.273.52.35238 9857063
Penela P, Ruiz-Gómez A, Castaño JG, Mayor F Jr. Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway. J Biol Chem. 1998;273:35238–44.9857063 10.1074/jbc.273.52.35238
146. Zha Z Han XR Smith MD Lei QY Guan KL Xiong Y Hypertension-associated C825T polymorphism impairs the function of Gβ3 to target GRK2 ubiquitination Cell Discov 2016 2 16005 10.1038/celldisc.2016.5 27462452
Zha Z, Han XR, Smith MD, Lei QY, Guan KL, Xiong Y. Hypertension-associated C825T polymorphism impairs the function of Gβ3 to target GRK2 ubiquitination. Cell Discov. 2016;2:16005.27462452 10.1038/celldisc.2016.5
147. Banday AA Lokhandwala MF Oxidative stress reduces renal dopamine D1 receptor-Gq/11alpha G protein-phospholipase C signaling involving G protein-coupled receptor kinase 2 Am J Physiol Ren Physiol 2007 293 F306 F315 10.1152/ajprenal.00108.2007
Banday AA, Lokhandwala MF. Oxidative stress reduces renal dopamine D1 receptor-Gq/11alpha G protein-phospholipase C signaling involving G protein-coupled receptor kinase 2. Am J Physiol Ren Physiol. 2007;293:F306–F315.10.1152/ajprenal.00108.2007
148. Yu P Asico LD Luo Y Andrews P Eisner GM Hopfer U D1 dopamine receptor hyperphosphorylation in renal proximal tubules in hypertension Kidney Int 2006 70 1072 9 10.1038/sj.ki.5001708 16850019
Yu P, Asico LD, Luo Y, Andrews P, Eisner GM, Hopfer U, et al. D1 dopamine receptor hyperphosphorylation in renal proximal tubules in hypertension. Kidney Int. 2006;70:1072–9.16850019 10.1038/sj.ki.5001708
149. Villar VA Armando I Sanada H Frazer LC Russo CM Notario PM Novel role of sorting nexin 5 in renal D1 dopamine receptor trafficking and function: implications for hypertension FASEB J 2013 27 1808 19 10.1096/fj.12-208439 23195037
Villar VA, Armando I, Sanada H, Frazer LC, Russo CM, Notario PM, et al. Novel role of sorting nexin 5 in renal D1 dopamine receptor trafficking and function: implications for hypertension. FASEB J. 2013;27:1808–19.23195037 10.1096/fj.12-208439
150. Tiu AC Yang J Asico LD Konkalmatt P Zheng X Cuevas S Lipid rafts are required for effective renal D1 dopamine receptor function FASEB J 2020 34 6999 7017 10.1096/fj.201902710RR 32259353
Tiu AC, Yang J, Asico LD, Konkalmatt P, Zheng X, Cuevas S, et al. Lipid rafts are required for effective renal D1 dopamine receptor function. FASEB J. 2020;34:6999–7017.32259353 10.1096/fj.201902710RR
151. Yang J Villar VAM Rozyyev S Jose PA Zeng C The emerging role of sorting nexins in cardiovascular diseases Clin Sci 2019 133 723 37 10.1042/CS20190034
Yang J, Villar VAM, Rozyyev S, Jose PA, Zeng C. The emerging role of sorting nexins in cardiovascular diseases. Clin Sci. 2019;133:723–37.10.1042/CS20190034
152. Okawa T Aramaki Y Yamamoto M Kobayashi T Fukumoto S Toyoda Y Design, synthesis, and evaluation of the highly selective and potent G-protein-coupled receptor kinase 2 (GRK2) inhibitor for the potential treatment of heart failure J Med Chem 2017 60 6942 90 10.1021/acs.jmedchem.7b00443 28699740
Okawa T, Aramaki Y, Yamamoto M, Kobayashi T, Fukumoto S, Toyoda Y, et al. Design, synthesis, and evaluation of the highly selective and potent G-protein-coupled receptor kinase 2 (GRK2) inhibitor for the potential treatment of heart failure. J Med Chem. 2017;60:6942–90.28699740 10.1021/acs.jmedchem.7b00443
153. Thal DM Homan KT Chen J Wu EK Hinkle PM Huang ZM Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility ACS Chem Biol 2012 7 1830 9 10.1021/cb3003013 22882301
Thal DM, Homan KT, Chen J, Wu EK, Hinkle PM, Huang ZM, et al. Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol. 2012;7:1830–9.22882301 10.1021/cb3003013
154. Sun X Zhou M Wen G Huang Y Wu J Peng L Paroxetine attenuates cardiac hypertrophy via blocking GRK2 and ADRB1 interaction in hypertension J Am Heart Assoc 2021 10 e016364 10.1161/JAHA.120.016364 33372534
Sun X, Zhou M, Wen G, Huang Y, Wu J, Peng L, et al. Paroxetine attenuates cardiac hypertrophy via blocking GRK2 and ADRB1 interaction in hypertension. J Am Heart Assoc. 2021;10:e016364.33372534 10.1161/JAHA.120.016364
155. Carotenuto A Cipolletta E Gomez-Monterrey I Sala M Vernieri E Limatola A Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors Eur J Med Chem 2013 69 384 92 10.1016/j.ejmech.2013.08.039 24077529
Carotenuto A, Cipolletta E, Gomez-Monterrey I, Sala M, Vernieri E, Limatola A, et al. Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors. Eur J Med Chem. 2013;69:384–92.24077529 10.1016/j.ejmech.2013.08.039
156. Ciccarelli M Sorriento D Fiordelisi A Gambardella J Franco A Del Giudice C Pharmacological inhibition of GRK2 improves cardiac metabolism and function in experimental heart failure ESC Heart Fail 2020 7 1571 84 10.1002/ehf2.12706 32352228
Ciccarelli M, Sorriento D, Fiordelisi A, Gambardella J, Franco A, Del Giudice C, et al. Pharmacological inhibition of GRK2 improves cardiac metabolism and function in experimental heart failure. ESC Heart Fail. 2020;7:1571–84.32352228 10.1002/ehf2.12706
157. Rainbow RD Brennan S Jackson R Beech AJ Bengreed A Waldschmidt HV Small-molecule G protein-coupled receptor kinase inhibitors attenuate G protein-coupled receptor kinase 2-mediated desensitization of vasoconstrictor-induced arterial contractions Mol Pharm 2018 94 1079 91 10.1124/mol.118.112524
Rainbow RD, Brennan S, Jackson R, Beech AJ, Bengreed A, Waldschmidt HV, et al. Small-molecule G protein-coupled receptor kinase inhibitors attenuate G protein-coupled receptor kinase 2-mediated desensitization of vasoconstrictor-induced arterial contractions. Mol Pharm. 2018;94:1079–91.10.1124/mol.118.112524
158. Echeverría E Velez Rueda AJ Cabrera M Juritz E Burghi V Fabián L Identification of inhibitors of the RGS homology domain of GRK2 by docking-based virtual screening Life Sci 2019 239 116872 10.1016/j.lfs.2019.116872 31525427
Echeverría E, Velez Rueda AJ, Cabrera M, Juritz E, Burghi V, Fabián L, et al. Identification of inhibitors of the RGS homology domain of GRK2 by docking-based virtual screening. Life Sci. 2019;239:116872.31525427 10.1016/j.lfs.2019.116872
159. Echeverría E Ripoll S Fabián L Shayo C Monczor F Fernández NC Novel inhibitors of phosphorylation independent activity of GRK2 modulate cAMP signaling Pharm Res Perspect 2022 10 e00913 10.1002/prp2.913
Echeverría E, Ripoll S, Fabián L, Shayo C, Monczor F, Fernández NC. Novel inhibitors of phosphorylation independent activity of GRK2 modulate cAMP signaling. Pharm Res Perspect. 2022;10:e00913.10.1002/prp2.913
160. Waldschmidt HV Bouley R Kirchhoff PD Lee P Tesmer JJG Larsen SD Utilizing a structure-based docking approach to develop potent G protein-coupled receptor kinase (GRK) 2 and 5 inhibitors Bioorg Med Chem Lett 2018 28 1507 15 10.1016/j.bmcl.2018.03.082 29627263
Waldschmidt HV, Bouley R, Kirchhoff PD, Lee P, Tesmer JJG, Larsen SD. Utilizing a structure-based docking approach to develop potent G protein-coupled receptor kinase (GRK) 2 and 5 inhibitors. Bioorg Med Chem Lett. 2018;28:1507–15.29627263 10.1016/j.bmcl.2018.03.082
161. Wu Y Wang S Wang H Hu B Wang J Selectivity mechanism of GRK2/5 inhibition through in silico investigation Comput Biol Chem 2022 101 107786 10.1016/j.compbiolchem.2022.107786 36399961
Wu Y, Wang S, Wang H, Hu B, Wang J. Selectivity mechanism of GRK2/5 inhibition through in silico investigation. Comput Biol Chem. 2022;101:107786.36399961 10.1016/j.compbiolchem.2022.107786
162. Homan KT Waldschmidt HV Glukhova A Cannavo A Song J Cheung JY Crystal structure of G protein-coupled receptor kinase 5 in complex with a rationally designed inhibitor J Biol Chem 2015 290 20649 59 10.1074/jbc.M115.647370 26032411
Homan KT, Waldschmidt HV, Glukhova A, Cannavo A, Song J, Cheung JY, et al. Crystal structure of G protein-coupled receptor kinase 5 in complex with a rationally designed inhibitor. J Biol Chem. 2015;290:20649–59.26032411 10.1074/jbc.M115.647370
163. Duarte JD Cavallari LH Pharmacogenetics to guide cardiovascular drug therapy Nat Rev Cardiol 2021 18 649 65 10.1038/s41569-021-00549-w 33953382
Duarte JD, Cavallari LH. Pharmacogenetics to guide cardiovascular drug therapy. Nat Rev Cardiol. 2021;18:649–65.33953382 10.1038/s41569-021-00549-w
164. Vandell AG Lobmeyer MT Gawronski BE Langaee TY Gong Y Gums JG G protein receptor kinase 4 (RK4) polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension Hypertension 2012 60 957 64 10.1161/HYPERTENSIONAHA.112.198721 22949529
Vandell AG, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG, et al. G protein receptor kinase 4 (RK4) polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012;60:957–64.22949529 10.1161/HYPERTENSIONAHA.112.198721
165. Sanada H Yoneda M Yatabe J Williams SM Bartlett J White MJ Common variants of the G protein-coupled receptor type 4 are associate ed with human essential hypertension and predict the blood pressure response to angiotensin receptor blockade Pharmacogenom J 2016 16 3 9 10.1038/tpj.2015.6
Sanada H, Yoneda M, Yatabe J, Williams SM, Bartlett J, White MJ, et al. Common variants of the G protein-coupled receptor type 4 are associate ed with human essential hypertension and predict the blood pressure response to angiotensin receptor blockade. Pharmacogenom J. 2016;16:3–9.10.1038/tpj.2015.6
166. Cao N Tang H Tian M Gong X Xu Z Zhou B Genetic variants of GRK4 influence circadian rhythm of blood pressure and response to candesartan in hypertensive patients Clin Exp Hypertens 2021 43 597 603 10.1080/10641963.2021.1919357 33899625
Cao N, Tang H, Tian M, Gong X, Xu Z, Zhou B, et al. Genetic variants of GRK4 influence circadian rhythm of blood pressure and response to candesartan in hypertensive patients. Clin Exp Hypertens. 2021;43:597–603.33899625 10.1080/10641963.2021.1919357
167. Wagner F Malice MP Wiegert E McGrath HE Gildea J Mitta S A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans J Hypertens 2012 30 819 27 10.1097/HJH.0b013e32835022a8 22278145
Wagner F, Malice MP, Wiegert E, McGrath HE, Gildea J, Mitta S, et al. A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans. J Hypertens. 2012;30:819–27.22278145 10.1097/HJH.0b013e32835022a8
168. Muskalla AM Suter PM Saur M Nowak A Hersberger M Krayenbuehl PA G-protein receptor kinase 4 polymorphism and response to antihypertensive therapy Clin Chem 2014 60 1543 8 10.1373/clinchem.2014.226605 25301854
Muskalla AM, Suter PM, Saur M, Nowak A, Hersberger M, Krayenbuehl PA. G-protein receptor kinase 4 polymorphism and response to antihypertensive therapy. Clin Chem. 2014;60:1543–8.25301854 10.1373/clinchem.2014.226605
169. Rayner B Ramesar R Steyn K Levitt N Lombard C Charlton K G-protein-coupled receptor kinase 4 polymorphisms predict blood pressure response to dietary modification in Black patients with mild-to-moderate hypertension J Hum Hypertens 2012 26 334 9 10.1038/jhh.2011.33 21544086
Rayner B, Ramesar R, Steyn K, Levitt N, Lombard C, Charlton K. G-protein-coupled receptor kinase 4 polymorphisms predict blood pressure response to dietary modification in Black patients with mild-to-moderate hypertension. J Hum Hypertens. 2012;26:334–9.21544086 10.1038/jhh.2011.33
170. Xia X Zeng Y Li Z Luo H Wang W He Y Effect of GRK4 on renal gastrin receptor regulation in hypertension Clin Exp Hypertens 2023 45 2245580 10.1080/10641963.2023.2245580 37641972
Xia X, Zeng Y, Li Z, Luo H, Wang W, He Y, et al. Effect of GRK4 on renal gastrin receptor regulation in hypertension. Clin Exp Hypertens. 2023;45:2245580.37641972 10.1080/10641963.2023.2245580
171. Wang Y Li B Zhao W Liu P Zhao Q Chen S Association study of G protein-coupled receptor kinase 4 gene variants with essential hypertension in northern Han Chinese Ann Hum Genet 2006 70 778 83 10.1111/j.1469-1809.2006.00278.x 17044852
Wang Y, Li B, Zhao W, Liu P, Zhao Q, Chen S, et al. Association study of G protein-coupled receptor kinase 4 gene variants with essential hypertension in northern Han Chinese. Ann Hum Genet. 2006;70:778–83.17044852 10.1111/j.1469-1809.2006.00278.x
172. Montasser ME Shimmin LC Gu D Chen J Gu C Kelly TN Variation in genes that regulate blood pressure are associated with glomerular filtration rate in Chinese PLoS One 2014 9 e92468 10.1371/journal.pone.0092468 24658007
Montasser ME, Shimmin LC, Gu D, Chen J, Gu C, Kelly TN, et al. Variation in genes that regulate blood pressure are associated with glomerular filtration rate in Chinese. PLoS One. 2014;9:e92468.24658007 10.1371/journal.pone.0092468
173. Frey MK Dao F Olvera N Konner JA Dickler MN Levine DA Genetic predisposition to bevacizumab-induced hypertension Gynecol Oncol 2017 147 621 5 10.1016/j.ygyno.2017.09.017 28969913
Frey MK, Dao F, Olvera N, Konner JA, Dickler MN, Levine DA. Genetic predisposition to bevacizumab-induced hypertension. Gynecol Oncol. 2017;147:621–5.28969913 10.1016/j.ygyno.2017.09.017
174. Yaqub DA Moore SC Rozyyev S Konkalmatt P Asico LD Hunt J G protein-coupled receptor kinase 4 (GRK4) variant 65L-mediated impairment of dopamine D1 receptor function causes hypertension FASEB J 2021 35 03664 10.1096/fasebj.2021.35.S1.03664
Yaqub DA, Moore SC, Rozyyev S, Konkalmatt P, Asico LD, Hunt J, et al. G protein-coupled receptor kinase 4 (GRK4) variant 65L-mediated impairment of dopamine D1 receptor function causes hypertension. FASEB J. 2021;35:03664.10.1096/fasebj.2021.35.S1.03664
175. Rozyyev S Konkalmatt P Villar VA Asico LD Kumar M Hunt J Molecular mechanisms underlying the GRK4 65L-mediated hypertension in mice FASEB J 2019 33 597.2 10.1096/fasebj.2019.33.1_supplement.597.2
Rozyyev S, Konkalmatt P, Villar VA, Asico LD, Kumar M, Hunt J, et al. Molecular mechanisms underlying the GRK4 65L-mediated hypertension in mice. FASEB J. 2019;33:597.2.10.1096/fasebj.2019.33.1_supplement.597.2
176. Gainetdinov RR Bohn LM Sotnikova TD Cyr M Laakso A Macrae AD Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice Neuron 2003 38 291 303 10.1016/S0896-6273(03)00192-2 12718862
Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, et al. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron. 2003;38:291–303.12718862 10.1016/S0896-6273(03)00192-2
177. Kavelaars A Vroon A Raatgever RP Fong AM Premont RT Patel DD Increased acute inflammation, leukotriene B4-induced chemotaxis, and signaling in mice deficient for G protein-coupled receptor kinase 6 J Immunol 2003 171 6128 34 10.4049/jimmunol.171.11.6128 14634128
Kavelaars A, Vroon A, Raatgever RP, Fong AM, Premont RT, Patel DD, et al. Increased acute inflammation, leukotriene B4-induced chemotaxis, and signaling in mice deficient for G protein-coupled receptor kinase 6. J Immunol. 2003;171:6128–34.14634128 10.4049/jimmunol.171.11.6128
